1
|
Takeda K, Kawashima M, Masuda K, Kimura Y, Igei H, Kusaka K, Kitani M, Fukami T, Morio Y, Sasaki Y, Hebisawa A, Matsui H. A 65-Year-Old Man With Massive Hemoptysis. Chest 2023; 164:e9-e13. [PMID: 37423707 DOI: 10.1016/j.chest.2023.01.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2022] [Revised: 12/01/2022] [Accepted: 01/05/2023] [Indexed: 07/11/2023] Open
Abstract
CASE PRESENTATION A 65-year-old man experienced a cough and mild hemoptysis suddenly one morning. He was prescribed tranexamic acid and carbazochrome salicylate by the local clinic at the first visit, and his hemoptysis stopped. However, 2 days later, he experienced recurrent hemoptysis that was prolonged intermittently. He had slight dyspnea and chest discomfort, but no other symptoms, such as sputum, fever, or chest pain. He was referred to our hospital for further assessment of hemoptysis. He had experienced mild hemoptysis of unknown causes 8 years earlier without recurrence until this episode. He had bronchial asthma that was treated with an inhaled corticosteroid and hypertension and hyperuricemia that were untreated with medication. He had no known allergies or family history of lung disease. He did not smoke. The patient denied alcohol consumption, any recent travel, or exposure to TB.
Collapse
Affiliation(s)
- Keita Takeda
- Center for Pulmonary Diseases, National Hospital Organization Tokyo National Hospital, Tokyo, Japan; Center for Pulmonary Circulation and Hemoptysis, National Hospital Organization Tokyo National Hospital, Tokyo, Japan.
| | - Masahiro Kawashima
- Center for Pulmonary Diseases, National Hospital Organization Tokyo National Hospital, Tokyo, Japan; Center for Pulmonary Circulation and Hemoptysis, National Hospital Organization Tokyo National Hospital, Tokyo, Japan
| | - Kimihiko Masuda
- Center for Pulmonary Diseases, National Hospital Organization Tokyo National Hospital, Tokyo, Japan; Center for Pulmonary Circulation and Hemoptysis, National Hospital Organization Tokyo National Hospital, Tokyo, Japan
| | - Yuya Kimura
- Center for Pulmonary Diseases, National Hospital Organization Tokyo National Hospital, Tokyo, Japan
| | - Hiroshi Igei
- Center for Pulmonary Diseases, National Hospital Organization Tokyo National Hospital, Tokyo, Japan; Center for Pulmonary Circulation and Hemoptysis, National Hospital Organization Tokyo National Hospital, Tokyo, Japan
| | - Kei Kusaka
- Center for Pulmonary Diseases, National Hospital Organization Tokyo National Hospital, Tokyo, Japan; Center for Pulmonary Circulation and Hemoptysis, National Hospital Organization Tokyo National Hospital, Tokyo, Japan
| | - Masashi Kitani
- Department of Pathology, National Hospital Organization Tokyo National Hospital, Tokyo, Japan
| | - Takeshi Fukami
- Department of Thoracic Surgery, National Hospital Organization Tokyo National Hospital, Tokyo, Japan
| | - Yoshiteru Morio
- Center for Pulmonary Diseases, National Hospital Organization Tokyo National Hospital, Tokyo, Japan; Center for Pulmonary Circulation and Hemoptysis, National Hospital Organization Tokyo National Hospital, Tokyo, Japan
| | - Yuka Sasaki
- Center for Pulmonary Diseases, National Hospital Organization Tokyo National Hospital, Tokyo, Japan
| | - Akira Hebisawa
- Department of Pathology, National Hospital Organization Tokyo National Hospital, Tokyo, Japan
| | - Hirotoshi Matsui
- Center for Pulmonary Diseases, National Hospital Organization Tokyo National Hospital, Tokyo, Japan
| |
Collapse
|
2
|
Tanaka H, Tanzawa S, Misumi T, Makiguchi T, Inaba M, Honda T, Nakamura J, Inoue K, Kishikawa T, Nakashima M, Fujiwara K, Kohyama T, Ishida H, Kuyama S, Miyazawa N, Nakamura T, Miyawaki H, Oda N, Ishikawa N, Morinaga R, Kusaka K, Fujimoto N, Fukuda Y, Yasugi M, Tsuda T, Ushijima S, Shibata K, Shibayama T, Bessho A, Kaira K, Shiraishi K, Matsutani N, Seki N. A phase II study of S-1 and cisplatin with concurrent thoracic radiotherapy followed by durvalumab for unresectable, locally advanced non-small-cell lung cancer in Japan (SAMURAI study): primary analysis. Ther Adv Med Oncol 2022; 14:17588359221142786. [PMID: 36570411 PMCID: PMC9772940 DOI: 10.1177/17588359221142786] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/10/2022] [Accepted: 11/16/2022] [Indexed: 12/23/2022] Open
Abstract
Background The standard of care for unresectable, locally advanced non-small-cell lung cancer (LA-NSCLC) is chemoradiotherapy (CRT) followed by durvalumab, based on the PACIFIC study. Although multiple Japanese phase II studies have shown high efficacy and tolerability of CRT with cisplatin plus S-1 (SP), no prospective study using durvalumab after SP-based CRT has been reported. Objectives We conducted a multicenter phase II study of this approach, the interim analysis of which showed a high transition rate to durvalumab consolidation therapy. Here, we report the primary analysis results. Design In treatment-naïve LA-NSCLC, cisplatin (60 mg/m2, day 1) and S-1 (80-120 mg/body, days 1-14) were administered with two 4-week cycles with concurrent thoracic radiotherapy (60 Gy) followed by durvalumab (10 mg/kg) every 2 weeks for up to 1 year. Methods The primary endpoint was 1-year progression-free survival (PFS). The expected 1-year PFS and its lower limit of the 80% confidence interval (CI) were set as 63% and 47%, respectively, based on the results of TORG1018 study. Results In all, 59 patients were enrolled, with 51 (86.4%) proceeding to durvalumab. The objective response rate throughout the study was 72.9% (95% CI: 59.7-83.6%). After median follow-up of 21.9 months, neither median PFS nor OS was reached. The 1-year PFS was 72.5% (80% CI: 64.2-79.2%, 95% CI: 59.1-82.2%), while the 1-year overall survival was 91.5% (95% CI: 80.8-96.4%). No grade 5 adverse events were observed throughout the study. The most common adverse event during the consolidation phase was pneumonitis (any grade, 78.4%; grade ⩾3, 2.0%). Eventually, 52.5% of patients completed 1-year durvalumab consolidation therapy from CRT initiation. Conclusion This study of durvalumab after SP-based CRT met its primary endpoint and found a 1-year PFS of 73% from CRT initiation. This study provides the first prospective data on the prognosis and tolerability of durvalumab consolidation from the initiation of CRT. Trial registration Japan Registry of Clinical Trials, jRCTs031190127, registered 1 November, 2019, https://jrct.niph.go.jp/latest-detail/jRCTs031190127.
Collapse
Affiliation(s)
| | | | - Toshihiro Misumi
- Department of Biostatistics, Yokohama City University School of Medicine, Yokohama, Kanagawa, Japan
| | - Tomonori Makiguchi
- Department of Respiratory Medicine, Hirosaki University Graduate School of Medicine, Hirosaki, Aomori, Japan
| | - Megumi Inaba
- Department of Respiratory Medicine, Kumamoto Chuo Hospital, Kumamoto, Kumamoto, Japan
| | - Takeshi Honda
- Division of Medical Oncology, Department of Internal Medicine, Teikyo University School of Medicine, Itabashi-ku, Tokyo, Japan
| | - Junya Nakamura
- Department of Respiratory Medicine, Ehime Prefectural Central Hospital, Matsuyama, Ehime, Japan
| | - Koji Inoue
- Department of Respiratory Medicine, Ehime Prefectural Central Hospital, Matsuyama, Ehime, Japan
| | - Takayuki Kishikawa
- Department of Respiratory Medicine, Tochigi Cancer Center, Utsunomiya, Tochigi, Japan
| | - Masanao Nakashima
- Department of Respiratory Medicine, Shin-Yurigaoka General Hospital, Kawasaki, Kanagawa, Japan
| | - Keiichi Fujiwara
- Department of Respiratory Medicine, National Hospital Organization Okayama Medical Center, Okayama, Okayama, Japan
| | - Tadashi Kohyama
- Department of Internal Medicine, Teikyo University Hospital, Mizonokuchi, Kawasaki, Kanagawa, Japan
| | - Hiroo Ishida
- Department of Internal Medicine, Showa University Northern Yokohama Hospital, Yokohama, Kanagawa, Japan
| | - Shoichi Kuyama
- Department of Respiratory Medicine, National Hospital Organization Iwakuni Clinical Center, Iwakuni, Yamaguchi, Japan
| | - Naoki Miyazawa
- Department of Respiratory Medicine, Saiseikai Yokohamashi Nanbu Hospital, Yokohama, Kanagawa, Japan
| | - Tomomi Nakamura
- Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, Saga, Saga, Japan
| | - Hiroshi Miyawaki
- Department of Respiratory Medicine, Kagawa Prefectural Central Hospital, Takamatsu, Kagawa, Japan
| | - Naohiro Oda
- Department of Internal Medicine, Fukuyama City Hospital, Fukuyama, Hiroshima, Japan
| | - Nobuhisa Ishikawa
- Department of Respiratory Medicine, Hiroshima Prefectural Hospital, Hiroshima, Hiroshima, Japan
| | - Ryotaro Morinaga
- Department of Thoracic Medical Oncology, Oita Prefectural Hospital, Oita, Oita, Japan
| | - Kei Kusaka
- The Center for Pulmonary Diseases, National Hospital Organization Tokyo National Hospital, Kiyose, Tokyo, Japan
| | - Nobukazu Fujimoto
- Department of Medical Oncology, Okayama Rosai Hospital, Okayama, Okayama, Japan
| | - Yasushi Fukuda
- Department of Respiratory Medicine, Kurashiki Central Hospital, Kurashiki, Okayama, Japan
| | - Masayuki Yasugi
- Department of Respiratory Medicine, Chugoku Central Hospital, Fukuyama, Hiroshima, Japan
| | - Takeshi Tsuda
- Department of Respiratory Medicine, Toyama Prefectural Central Hospital, Toyama, Toyama, Japan
| | - Sunao Ushijima
- Department of Medical Oncology, Kumamoto Kenhoku Hospital, Tamana, Kumamoto, Japan
| | - Kazuhiko Shibata
- Department of Medical Oncology, Kouseiren Takaoka Hospital, Takaoka, Toyama, Japan
| | - Takuo Shibayama
- Department of Respiratory Medicine, National Hospital Organization Okayama Medical Center, Okayama, Okayama, Japan
| | - Akihiro Bessho
- Department of Respiratory Medicine, Japanese Red Cross Okayama Hospital, Okayama, Okayama, Japan
| | - Kyoichi Kaira
- Department of Respiratory Medicine, Saitama Medical University International Medical Center, Hidaka, Saitama, Japan
| | - Kenshiro Shiraishi
- Department of Radiology, Teikyo University School of Medicine, Itabashi-ku, Tokyo, Japan
| | - Noriyuki Matsutani
- Department of Surgery, Teikyo University Hospital, Mizonokuchi, Kawasaki, Kanagawa, Japan
| | | |
Collapse
|
3
|
Ahn DS, Amano J, Baba H, Fukuda N, Geissel H, Inabe N, Ishikawa S, Iwasa N, Komatsubara T, Kubo T, Kusaka K, Morrissey DJ, Nakamura T, Ohtake M, Otsu H, Sakakibara T, Sato H, Sherrill BM, Shimizu Y, Sumikama T, Suzuki H, Takeda H, Tarasov OB, Ueno H, Yanagisawa Y, Yoshida K. Discovery of ^{39}Na. Phys Rev Lett 2022; 129:212502. [PMID: 36461972 DOI: 10.1103/physrevlett.129.212502] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/14/2022] [Revised: 09/08/2022] [Accepted: 09/14/2022] [Indexed: 06/17/2023]
Abstract
The new isotope ^{39}Na, the most neutron-rich sodium nucleus observed so far, was discovered at the RIKEN Nishina Center Radioactive Isotope Beam Factory using the projectile fragmentation of an intense ^{48}Ca beam at 345 MeV/nucleon on a beryllium target. Projectile fragments were separated and identified in flight with the large-acceptance two-stage separator BigRIPS. Nine ^{39}Na events have been unambiguously observed in this work and clearly establish the particle stability of ^{39}Na. Furthermore, the lack of observation of ^{35,36}Ne isotopes in this experiment significantly improves the overall confidence that ^{34}Ne is the neutron dripline nucleus of neon. These results provide new key information to understand nuclear binding and nuclear structure under extremely neutron-rich conditions. The newly established stability of ^{39}Na has a significant impact on nuclear models and theories predicting the neutron dripline and also provides a key to understanding the nuclear shell property of ^{39}Na at the neutron number N=28, which is normally a magic number.
Collapse
Affiliation(s)
- D S Ahn
- RIKEN Nishina Center for Accelerator-Based Science, RIKEN, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - J Amano
- Department of Physics, Rikkyo University, 3-34-1 Nishi-Ikebukuro, Toshima, Tokyo 171-8501, Japan
| | - H Baba
- RIKEN Nishina Center for Accelerator-Based Science, RIKEN, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - N Fukuda
- RIKEN Nishina Center for Accelerator-Based Science, RIKEN, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - H Geissel
- GSI, Helmholtzzentrum für Schwerionenforschung GmbH, Planckstraße 1, 64291 Darmstadt, Germany
| | - N Inabe
- RIKEN Nishina Center for Accelerator-Based Science, RIKEN, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - S Ishikawa
- Department of Physics, Tohoku University, 6-3, Aramaki Aza-Aoba, Aoba-ku, Sendai, Miyagi 980-8578, Japan
| | - N Iwasa
- Department of Physics, Tohoku University, 6-3, Aramaki Aza-Aoba, Aoba-ku, Sendai, Miyagi 980-8578, Japan
| | - T Komatsubara
- RIKEN Nishina Center for Accelerator-Based Science, RIKEN, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - T Kubo
- RIKEN Nishina Center for Accelerator-Based Science, RIKEN, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - K Kusaka
- RIKEN Nishina Center for Accelerator-Based Science, RIKEN, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - D J Morrissey
- National Superconducting Cyclotron Laboratory, Michigan State University, 640 South Shaw Lane, East Lansing, Michigan 48824, USA
| | - T Nakamura
- Department of Physics, Tokyo Institute of Technology, 2-12-1 O-Okayama, Meguro, Tokyo 152-8551, Japan
| | - M Ohtake
- RIKEN Nishina Center for Accelerator-Based Science, RIKEN, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - H Otsu
- RIKEN Nishina Center for Accelerator-Based Science, RIKEN, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - T Sakakibara
- Department of Physics, Tohoku University, 6-3, Aramaki Aza-Aoba, Aoba-ku, Sendai, Miyagi 980-8578, Japan
| | - H Sato
- RIKEN Nishina Center for Accelerator-Based Science, RIKEN, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - B M Sherrill
- National Superconducting Cyclotron Laboratory, Michigan State University, 640 South Shaw Lane, East Lansing, Michigan 48824, USA
| | - Y Shimizu
- RIKEN Nishina Center for Accelerator-Based Science, RIKEN, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - T Sumikama
- RIKEN Nishina Center for Accelerator-Based Science, RIKEN, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - H Suzuki
- RIKEN Nishina Center for Accelerator-Based Science, RIKEN, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - H Takeda
- RIKEN Nishina Center for Accelerator-Based Science, RIKEN, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - O B Tarasov
- National Superconducting Cyclotron Laboratory, Michigan State University, 640 South Shaw Lane, East Lansing, Michigan 48824, USA
| | - H Ueno
- RIKEN Nishina Center for Accelerator-Based Science, RIKEN, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - Y Yanagisawa
- RIKEN Nishina Center for Accelerator-Based Science, RIKEN, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - K Yoshida
- RIKEN Nishina Center for Accelerator-Based Science, RIKEN, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| |
Collapse
|
4
|
Tanzawa S, Makiguchi T, Tasaka S, Inaba M, Ochiai R, Nakamura J, Inoue K, Kishikawa T, Nakashima M, Fujiwara K, Kohyama T, Ishida H, Kuyama S, Miyazawa N, Nakamura T, Miyawaki H, Oda N, Ishikawa N, Morinaga R, Kusaka K, Miyamoto Y, Yokoyama T, Matsumoto C, Tsuda T, Ushijima S, Shibata K, Shibayama T, Bessho A, Kaira K, Misumi T, Shiraishi K, Matsutani N, Seki N. Prospective analysis of factors precluding the initiation of durvalumab from an interim analysis of a phase II trial of S-1 and cisplatin with concurrent thoracic radiotherapy followed by durvalumab for unresectable, locally advanced non-small cell lung cancer in Japan (SAMURAI study). Ther Adv Med Oncol 2022; 14:17588359221116603. [PMID: 35923924 PMCID: PMC9340896 DOI: 10.1177/17588359221116603] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/07/2022] [Accepted: 07/12/2022] [Indexed: 11/22/2022] Open
Abstract
Background: The standard of care for unresectable, locally advanced non-small cell lung cancer (LA-NSCLC) is chemoradiotherapy (CRT) followed by durvalumab, based on the PACIFIC trial. Disease progression and pneumonitis were reported as the main reasons to preclude the initiation of durvalumab in multiple retrospective studies. However, the transition rate and the reasons for failure to proceed to consolidation therapy with durvalumab after CRT were not evaluated prospectively. Although phase II studies in Japan have shown high efficacy and tolerability of CRT with cisplatin + S-1 (SP), no prospective study using durvalumab after SP-based CRT has yet been reported. We therefore conducted a phase II study to verify the efficacy and safety of durvalumab following SP-based CRT. In this interim analysis, we report the transition rate and the reasons for its failure. Methods: In treatment-naïve LA-NSCLC, cisplatin (60 mg/m2, day 1) and S-1 (80–120 mg/body, days 1–14) were administered with two 4-week cycles with concurrent thoracic radiotherapy (60 Gy) followed by durvalumab every 2 weeks for up to 12 months. The primary endpoint was 12 month progression-free survival rate. Results: Fifty-nine patients were enrolled, of whom 86.4% (51/59) proceeded to durvalumab. All of them initiated durvalumab within 42 days after CRT [median 18 days (range: 3–38)], including 27.5% (14/51) in <14 days. Common reasons for failure to proceed to durvalumab were disease progression (2/59, 3.4%) and adverse events (6/59, 10.2%). Among the latter cases, four resumed treatment and proceeded to durvalumab within 42 days on off-protocol. The objective response rate and the disease control rate were 62.7% and 93.2%, respectively. The incidences of ⩾grade 3 pneumonitis, febrile neutropenia, and esophagitis were 0%, 8.5%, and 3.4%, respectively. Conclusion: Regarding durvalumab after CRT, this interim analysis of the SAMURAI study clarified the high transition rate, early introduction, and reasons for failure to proceed to consolidation therapy, which were not determined in the PACIFIC trial. Trial registration: Japan Registry of Clinical Trials, jRCTs031190127, registered 1 November, 2019, https://jrct.niph.go.jp/latest-detail/jRCTs031190127.
Collapse
Affiliation(s)
- Shigeru Tanzawa
- Division of Medical Oncology, Department of Internal Medicine, Teikyo University School of Medicine, Itabashi-ku, Tokyo, Japan
| | - Tomonori Makiguchi
- Department of Respiratory Medicine, Hirosaki University Graduate School of Medicine, Hirosaki, Aomori, Japan
| | - Sadatomo Tasaka
- Department of Respiratory Medicine, Hirosaki University Graduate School of Medicine, Hirosaki, Aomori, Japan
| | - Megumi Inaba
- Department of Respiratory Medicine, Kumamoto Chuo Hospital, Kumamoto, Kumamoto, Japan
| | - Ryosuke Ochiai
- Division of Medical Oncology, Department of Internal Medicine, Teikyo University School of Medicine, Itabashi-ku, Tokyo, Japan
| | - Junya Nakamura
- Department of Respiratory Medicine, Ehime Prefectural Central Hospital, Matsuyama, Ehime, Japan
| | - Koji Inoue
- Department of Respiratory Medicine, Ehime Prefectural Central Hospital, Matsuyama, Ehime, Japan
| | - Takayuki Kishikawa
- Department of Respiratory Medicine, Tochigi Cancer Center, Utsunomiya, Tochigi, Japan
| | - Masanao Nakashima
- Department of Respiratory Medicine, Shin-Yurigaoka General Hospital, Kawasaki, Kanagawa, Japan
| | - Keiichi Fujiwara
- Department of Respiratory Medicine, National Hospital Organization Okayama Medical Center, Okayama, Okayama, Japan
| | - Tadashi Kohyama
- Department of Internal medicine, Teikyo University Mizonokuchi Hospital, Kawasaki, Kanagawa, Japan
| | - Hiroo Ishida
- Department of Internal Medicine, Showa University Northern Yokohama Hospital, Yokohama, Kanagawa, Japan
| | - Shoichi Kuyama
- Department of Respiratory Medicine, National Hospital Organization Iwakuni Clinical Center, Iwakuni, Yamaguchi, Japan
| | - Naoki Miyazawa
- Department of Respiratory Medicine, Saiseikai Yokohamashi Nanbu Hospital, Yokohama, Kanagawa, Japan
| | - Tomomi Nakamura
- Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, Saga, Saga, Japan
| | - Hiroshi Miyawaki
- Department of Respiratory Medicine, Kagawa Prefectural Central Hospital, Takamatsu, Kagawa, Japan
| | - Naohiro Oda
- Department of Internal medicine, Fukuyama City Hospital, Fukuyama, Hiroshima, Japan
| | - Nobuhisa Ishikawa
- Department of Respiratory Medicine, Hiroshima Prefectural Hospital, Hiroshima, Hiroshima, Japan
| | - Ryotaro Morinaga
- Department of Thoracic Medical Oncology, Oita Prefectural Hospital, Oita, Oita, Japan
| | - Kei Kusaka
- The Center for Pulmonary Diseases, National Hospital Organization Tokyo National Hospital, Kiyose, Tokyo, Japan
| | - Yosuke Miyamoto
- Department of Medical Oncology, Okayama Rosai Hospital, Okayama, Okayama, Japan
| | - Toshihide Yokoyama
- Department of Respiratory Medicine, Kurashiki Central Hospital, Kurashiki, Okayama, Japan
| | - Chiaki Matsumoto
- Department of Respiratory Medicine, Chugoku Central Hospital, Fukuyama, Hiroshima, Japan
| | - Takeshi Tsuda
- Department of Respiratory Medicine, Toyama Prefectural Central Hospital, Toyama, Toyama, Japan
| | - Sunao Ushijima
- Department of Medical Oncology, Kumamoto Kenhoku Hospital, Tamana, Kumamoto, Japan
| | - Kazuhiko Shibata
- Department of Medical Oncology, Kouseiren Takaoka Hospital, Takaoka, Toyama, Japan
| | - Takuo Shibayama
- Department of Respiratory Medicine, National Hospital Organization Okayama Medical Center, Okayama, Okayama, Japan
| | - Akihiro Bessho
- Department of Respiratory Medicine, Japanese Red Cross Okayama Hospital, Okayama, Okayama, Japan
| | - Kyoichi Kaira
- Department of Respiratory Medicine, Saitama Medical University International Medical Center, Hidaka, Saitama, Japan
| | - Toshihiro Misumi
- Department of Biostatistics, Yokohama City University School of Medicine, Yokohama, Kanagawa, Japan
| | - Kenshiro Shiraishi
- Department of Radiology, Teikyo University School of Medicine, Itabashi-ku, Tokyo, Japan
| | - Noriyuki Matsutani
- Department of Surgery, Teikyo University Mizonokuchi Hospital, Kawasaki, Kanagawa, Japan
| | - Nobuhiko Seki
- Division of Medical Oncology, Department of Internal Medicine, Teikyo University School of Medicine, 2-11-1, Kaga, Itabashi-ku, Tokyo 173-8605, Japan
| |
Collapse
|
5
|
Tanzawa S, Ushijima S, Shibata K, Shibayama T, Bessho A, Kaira K, Misumi T, Shiraishi K, Matsutani N, Tanaka H, Inaba M, Haruyama T, Nakamura J, Kishikawa T, Nakashima M, Iwasa K, Fujiwara K, Kohyama T, Kuyama S, Miyazawa N, Nakamura T, Miyawaki H, Ishida H, Oda N, Ishikawa N, Morinaga R, Kusaka K, Fujimoto N, Yokoyama T, Gemba K, Tsuda T, Nakagawa H, Ono H, Shimizu T, Nakamura M, Kusumoto S, Hayashi R, Shirasaki H, Ochi N, Aoe K, Kanaji N, Kashiwabara K, Inoue H, Seki N. A phase II study of S-1 and cisplatin with concurrent thoracic radiotherapy followed by durvalumab for unresectable, locally advanced non-small-cell lung cancer in Japan (SAMURAI study). Ther Adv Med Oncol 2021; 13:1758835921998588. [PMID: 33717228 PMCID: PMC7917867 DOI: 10.1177/1758835921998588] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/10/2020] [Accepted: 02/03/2021] [Indexed: 11/16/2022] Open
Abstract
Background: Based on the results of the PACIFIC study, chemoradiotherapy followed by
1-year consolidation therapy with durvalumab was established as the standard
of care for unresectable, locally advanced non-small-cell lung cancer
(LA-NSCLC). However, some topics not foreseen in that design can be
explored, including progression-free survival (PFS) and overall survival
(OS) after the start of chemoradiotherapy, the proportion of patients who
proceeded to consolidation therapy with durvalumab, and the optimal
chemotherapeutic regimens. In Japan, the combination regimen of
S-1 + cisplatin (SP), for which the results of multiple clinical studies
have suggested a good balance of efficacy and tolerability, is frequently
selected in clinical settings. However, the efficacy and safety of
consolidation therapy with durvalumab following this SP regimen have not
been evaluated. We therefore planned a multicenter, prospective, single-arm,
phase II study. Methods: In treatment-naïve LA-NSCLC, two cycles of combination chemotherapy with S-1
(80–120 mg/body, Days 1–14) + cisplatin (60 mg/m2, Day 1) will be
administered at an interval of 4 weeks, with concurrent thoracic
radiotherapy (60 Gy). Responders will then receive durvalumab every 2 weeks
for up to 1 year. The primary endpoint is 1-year PFS rate. Discussion: Compared with the conventional standard regimen in Japan, the SP regimen is
expected to be associated with lower incidences of pneumonitis, esophagitis,
and febrile neutropenia, which complicate the initiation of consolidation
therapy with durvalumab, and have higher antitumor efficacy during
chemoradiotherapy. Therefore, SP-based chemoradiotherapy is expected to be
successfully followed by consolidation therapy with durvalumab in more
patients, resulting in prolonged PFS and OS. Toxicity and efficacy results
of the SP regimen in this study will also provide information important to
the future establishment of the concurrent combination of chemoradiotherapy
and durvalumab. Trial registration: Japan Registry of Clinical Trials, jRCTs031190127, registered 1 November
2019, https://jrct.niph.go.jp/latest-detail/jRCTs031190127
Collapse
Affiliation(s)
- Shigeru Tanzawa
- Division of Medical Oncology, Department of Internal Medicine, Teikyo University School of Medicine, Itabashi-City, Tokyo, Japan
| | - Sunao Ushijima
- Department of Medical Oncology, Kumamoto Chuo Hospital, Kumamoto-City, Kumamoto, Japan
| | - Kazuhiko Shibata
- Department of Medical Oncology, Kouseiren Takaoka Hospital, Takaoka-City, Toyama, Japan
| | - Takuo Shibayama
- Department of Respiratory Medicine, National Hospital Organization Okayama Medical Center, Okayama-City, Okayama, Japan
| | - Akihiro Bessho
- Department of Respiratory Medicine, Japanese Red Cross Okayama Hospital, Okayama-City, Okayama, Japan
| | - Kyoichi Kaira
- Department of Respiratory Medicine, Saitama Medical University International Medical Center, Hidaka-City, Saitama, Japan
| | - Toshihiro Misumi
- Department of Biostatistics, Yokohama City University School of Medicine, Yokohama-City, Kanagawa, Japan
| | - Kenshiro Shiraishi
- Department of Radiology, Teikyo University School of Medicine, Itabashi-City, Tokyo, Japan
| | - Noriyuki Matsutani
- Department of Surgery, Teikyo University Mizonokuchi Hospital, Kawasaki-City, Kanagawa, Japan
| | - Hisashi Tanaka
- Department of Respiratory Medicine, Hirosaki University Graduate School of Medicine, Hirosaki-City, Aomori, Japan
| | - Megumi Inaba
- Department of Respiratory Medicine, Kumamoto Chuo Hospital, Kumamoto-City, Kumamoto, Japan
| | - Terunobu Haruyama
- Division of Medical Oncology, Department of Internal Medicine, Teikyo University School of Medicine, Itabashi-City, Tokyo, Japan
| | - Junya Nakamura
- Department of Respiratory Medicine, Ehime Prefectural Central Hospital, Matsuyama-City, Ehime, Japan
| | - Takayuki Kishikawa
- Division of Thoracic Oncology, Department of Medical Oncology, Tochigi Cancer Center, Utsunomiya-City, Tochigi, Japan
| | - Masanao Nakashima
- Department of Respiratory Medicine, Shin-Yurigaoka General Hospital, Kawasaki-City, Kanagawa, Japan
| | - Keiichi Iwasa
- Department of Medical Oncology, Kouseiren Takaoka Hospital, Takaoka-City, Toyama, Japan
| | - Keiichi Fujiwara
- Department of Respiratory Medicine, National Hospital Organization Okayama Medical Center, Okayama-City, Okayama, Japan
| | - Tadashi Kohyama
- Department of Internal medicine, Teikyo University Mizonokuchi Hospital, Kawasaki-City, Kanagawa, Japan
| | - Shoichi Kuyama
- Department of Respiratory Medicine, National Hospital Organization Iwakuni Clinical Center, Iwakuni-City, Yamaguchi, Japan
| | - Naoki Miyazawa
- Department of Respiratory Medicine, Saiseikai Yokohamashi Nanbu Hospital, Yokohama-City, Kanagawa, Japan
| | - Tomomi Nakamura
- Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, Saga-City, Saga, Japan
| | - Hiroshi Miyawaki
- Department of Respiratory Medicine, Kagawa Prefectural Central Hospital, Takamatsu-City, Kagawa, Japan
| | - Hiroo Ishida
- Department of Internal Medicine, Showa University Northern Yokohama Hospital, Yokohama-City, Kanagawa, Japan
| | - Naohiro Oda
- Department of Internal Medicine, Fukuyama City Hospital, Fukuyama-City, Hiroshima, Japan
| | - Nobuhisa Ishikawa
- Department of Respiratory Medicine, Hiroshima Prefectural Hospital, Hiroshima-City, Hiroshima, Japan
| | - Ryotaro Morinaga
- Department of Thoracic Medical Oncology, Oita Prefectural Hospital, Oita-City, Oita, Japan
| | - Kei Kusaka
- The Center for Pulmonary Diseases, National Hospital Organization Tokyo National Hospital, Kiyose-City, Tokyo, Japan
| | - Nobukazu Fujimoto
- Department of Medical Oncology, Okayama Rosai Hospital, Okayama-City, Okayama, Japan
| | - Toshihide Yokoyama
- Department of Respiratory Medicine, Kurashiki Central Hospital, Kurashiki-City, Okayama, Japan
| | - Kenichi Gemba
- Department of Respiratory Medicine, Chugoku Central Hospital, Fukuyama-City, Hiroshima, Japan
| | - Takeshi Tsuda
- Department of Respiratory Medicine, Toyama Prefectural Central Hospital, Toyama-City, Toyama, Japan
| | - Hideyuki Nakagawa
- Department of Respiratory Medicine, National Hospital Organization, Hirosaki Hospital, Hirosaki-City, Aomori, Japan
| | - Hirotaka Ono
- Department of Respiratory Medicine, Tsuboi Hospital, Koriyama-City, Fukushima, Japan
| | - Tetsuo Shimizu
- Division of Respiratory Medicine, Department of Internal Medicine, Nihon University School of Medicine, Itabashi-City, Tokyo, Japan
| | - Morio Nakamura
- Department of Pulmonary Medicine, Tokyo Saiseikai Central Hospital, Minato-City, Tokyo, Japan
| | - Sojiro Kusumoto
- Division of Allergology and Respiratory Medicine, Showa University School of Medicine, Shinagawa-City, Tokyo, Japan
| | - Ryuji Hayashi
- Clinical Oncology, Toyama University Hospital, Toyama-City, Toyama, Japan
| | - Hiroki Shirasaki
- Department of Respiratory Medicine, Fukui-ken Saiseikai Hospital, Fukui-City, Fukui, Japan
| | - Nobuaki Ochi
- General Internal Medicine 4, Kawasaki Medical School, Okayama-City, Okayama, Japan
| | - Keisuke Aoe
- Department of Medical Oncology, National Hospital Organization Yamaguchi-Ube Medical Center, Ube-City, Yamaguchi, Japan
| | - Nobuhiro Kanaji
- Department of Internal Medicine, Division of Hematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University, Kida-gun, Kagawa, Japan
| | - Kosuke Kashiwabara
- Department of Respiratory Medicine, Kumamoto Regional Medical Center, Kumamoto-City, Kumamoto, Japan
| | - Hiroshi Inoue
- Department of Internal Medicine, Karatsu Red Cross Hospital, Karatsu-City, Saga, Japan
| | - Nobuhiko Seki
- Division of Medical Oncology, Department of Internal Medicine, Teikyo University School of Medicine, 2-11-1, Kaga, Itabashi-ku, Tokyo 173-8606, Japan
| |
Collapse
|
6
|
Tanabe N, Kumamaru H, Tamura Y, Taniguchi H, Emoto N, Yamada Y, Nishiyama O, Tsujino I, Kuraishi H, Nishimura Y, Kimura H, Inoue Y, Morio Y, Nakatsumi Y, Satoh T, Hanaoka M, Kusaka K, Sumitani M, Handa T, Sakao S, Kimura T, Kondoh Y, Nakayama K, Tanaka K, Ohira H, Nishimura M, Miyata H, Tatsumi K. Multi-Institutional Prospective Cohort Study of Patients With Pulmonary Hypertension Associated With Respiratory Diseases. Circ J 2021; 85:333-342. [PMID: 33536399 DOI: 10.1253/circj.cj-20-0939] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
BACKGROUND There is limited evidence for pulmonary arterial hypertension (PAH)-targeted therapy in patients with pulmonary hypertension associated with respiratory disease (R-PH). Therefore, we conducted a multicenter prospective study of patients with R-PH to examine real-world characteristics of responders by evaluating demographics, treatment backgrounds, and prognosis.Methods and Results:Among the 281 patients with R-PH included in this study, there was a treatment-naïve cohort of 183 patients with normal pulmonary arterial wedge pressure and 1 of 4 major diseases (chronic obstructive pulmonary diseases, interstitial pneumonia [IP], IP with connective tissue disease, or combined pulmonary fibrosis with emphysema); 43% of patients had mild ventilatory impairment (MVI), whereas 52% had a severe form of PH. 68% received PAH-targeted therapies (mainly phosphodiesterase-5 inhibitors). Among patients with MVI, those treated initially (i.e., within 2 months of the first right heart catheterization) had better survival than patients not treated initially (3-year survival 70.6% vs. 34.2%; P=0.01); there was no significant difference in survival in the group with severe ventilatory impairment (49.6% vs. 32.1%; P=0.38). Responders to PAH-targeted therapy were more prevalent in the group with MVI. CONCLUSIONS This first Japanese registry of R-PH showed that a high proportion of patients with MVI (PAH phenotype) had better survival if they received initial treatment with PAH-targeted therapies. Responders were predominant in the group with MVI.
Collapse
Affiliation(s)
- Nobuhiro Tanabe
- Department of Respirology, Graduate School of Medicine, Chiba University.,Pulmonary Hypertension Center, Saiseikai Narashino Hospital
| | - Hiraku Kumamaru
- Department of Healthcare Quality Assessment, Graduate School of Medicine, The University of Tokyo
| | - Yuichi Tamura
- Pulmonary Hypertension Center, International University of Health and Welfare Mita Hospital
| | | | - Noriaki Emoto
- Department of Clinical Pharmacy, Kobe Pharmaceutical University
| | - Yoshihito Yamada
- Department of Chest Medicine, Japan Railway Tokyo General Hospital
| | - Osamu Nishiyama
- Department of Respiratory Medicine and Allergology, Faculty of Medicine, Kindai University
| | - Ichizo Tsujino
- First Department of Medicine, Hokkaido University Hospital
| | | | - Yoshihiro Nishimura
- Division of Respiratory Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine
| | - Hiroshi Kimura
- Department of Advanced Medicine for Pulmonary Circulation and Respiratory Failure and Department of Respiratory Medicine, Nippon Medical School Graduate School of Medicine.,Department of Respiratory Medicine, Fukujuji Hospital, Japan Anti-Tuberculosis Association (JATA).,Second Department of Internal Medicine, Nara Medical University
| | - Yoshikazu Inoue
- Clinical Research Center, National Hospital Organization Kinki-Chuo Chest Medical Center
| | - Yoshiteru Morio
- Department of Respiratory Medicine, Juntendo University Graduate School of Medicine.,Center for Pulmonary Diseases and Respiratory Disease Division, National Hospital Organization Tokyo National Hospital
| | | | - Toru Satoh
- Division of Cardiology Department of Medicine, Kyorin University Hospital
| | - Masayuki Hanaoka
- First Department of Medicine, Shinshu University School of Medicine
| | - Kei Kusaka
- Center for Pulmonary Diseases and Respiratory Disease Division, National Hospital Organization Tokyo National Hospital
| | | | - Tomohiro Handa
- Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University
| | - Seiicihiro Sakao
- Department of Respirology, Graduate School of Medicine, Chiba University
| | - Tomoki Kimura
- Department of Respiratory Medicine and Allergy, Tosei General Hospital
| | - Yasuhiro Kondoh
- Department of Respiratory Medicine and Allergy, Tosei General Hospital
| | - Kazuhiko Nakayama
- Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine
| | - Kensuke Tanaka
- Department of Chest Medicine, Japan Railway Tokyo General Hospital
| | - Hiroshi Ohira
- First Department of Medicine, Hokkaido University Hospital
| | | | - Hiroaki Miyata
- Department of Health Policy and Management, Keio University School of Medicine
| | - Koichiro Tatsumi
- Department of Respirology, Graduate School of Medicine, Chiba University
| | | |
Collapse
|
7
|
Kato T, Akagawa S, Kusaka K, Kawashima M, Ohshima N, Kitani M, Hebisawa A, Matsui H. An autopsy case report of yellow nail syndrome coincided with primary biliary cholangitis. Respir Med Case Rep 2020; 32:101332. [PMID: 33511030 PMCID: PMC7817504 DOI: 10.1016/j.rmcr.2020.101332] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/20/2020] [Revised: 12/19/2020] [Accepted: 12/27/2020] [Indexed: 12/19/2022] Open
Abstract
Yellow nail syndrome (YNS) is a rare entity characterized by thickened yellowish nails, lymphedema and respiratory manifestations such as pleural effusion. Lymphatic dysfunction is considered as a cause of YNS. However, evidence of systemic dilatation/hyperplasia of lymphatics based on autopsy in YNS is not available. In this report, autopsy revealed dilatation and hyperplasia of lymphatic vessels in lungs, visceral and parietal pleurae, and intestines. We identified the direct opening of lymphatic vessels of the visceral pleura to the pleural cavity, which indicated the pathophysiology of uncontrollable pleural effusion in YNS. The current case was compromised with primary biliary cholangitis (PBC). The onset of PBC seemed to be related with the progression of YNS.
Collapse
Affiliation(s)
- Takafumi Kato
- Center for Pulmonary Diseases, National Hospital Organization Tokyo National Hospital, Tokyo, Japan
| | - Shinobu Akagawa
- Center for Pulmonary Diseases, National Hospital Organization Tokyo National Hospital, Tokyo, Japan
| | - Kei Kusaka
- Center for Pulmonary Diseases, National Hospital Organization Tokyo National Hospital, Tokyo, Japan
| | - Masahiro Kawashima
- Center for Pulmonary Diseases, National Hospital Organization Tokyo National Hospital, Tokyo, Japan
| | - Nobuharu Ohshima
- Center for Pulmonary Diseases, National Hospital Organization Tokyo National Hospital, Tokyo, Japan
| | - Masashi Kitani
- Division of Pathology, National Hospital Organization Tokyo National Hospital, Tokyo, Japan
| | - Akira Hebisawa
- Division of Pathology, National Hospital Organization Tokyo National Hospital, Tokyo, Japan
| | - Hirotoshi Matsui
- Center for Pulmonary Diseases, National Hospital Organization Tokyo National Hospital, Tokyo, Japan
| |
Collapse
|
8
|
Miyamoto S, Azuma K, Ishii H, Bessho A, Hosokawa S, Fukamatsu N, Kunitoh H, Ishii M, Tanaka H, Aono H, Nakahara Y, Kusaka K, Hosomi Y, Kikuchi N, Mori Y, Itani H, Hamada A, Yamada K, Okamoto H. Low-Dose Erlotinib Treatment in Elderly or Frail Patients With EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Multicenter Phase 2 Trial. JAMA Oncol 2020; 6:e201250. [PMID: 32407455 DOI: 10.1001/jamaoncol.2020.1250] [Citation(s) in RCA: 26] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Abstract
Importance Although the efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for EGFR gene mutation-positive non-small cell lung cancer is well established, optimal dosing remains to be established, especially in elderly or frail patients. Objective To investigate the efficacy and safety of low-dose erlotinib in elderly or frail patients with EGFR mutation-positive non-small cell lung cancer. Design, Setting, and Participants Single-arm phase 2 trial with the Southwest Oncology Group (SWOG) 2-stage design that enrolled frail patients from 21 Japanese institutions after meeting the inclusion criteria. Chemotherapy-naive patients with EGFR-activating mutation-positive non-small cell lung cancer who were considered frail based on age, the Charlson Comorbidity Index, and Eastern Cooperative Oncology Group performance status were eligible for the study. Interventions Patients were initially administered 50 mg/d erlotinib for 4 weeks, which was modified based on response or adverse events. Dose increase was permitted for patients with stable disease after 4 weeks. Main Outcomes and Measures The primary end point was the independent review committee-confirmed objective response rate (ORR) at the dose of 50 mg/d. The study also evaluated the pharmacokinetics of low-dose erlotinib and influence of ABCB1 gene polymorphisms. Results Eighty patients were enrolled, with a median (range) age of 80 (49-90) years; 54 (68%) were men. An independent review committee confirmed a significant ORR of 60.0% (90% CI, 50.2%-69.2%). The disease control rate was 90.0% (90% CI, 82.7%-94.9%), median progression-free survival was 9.3 months (95% CI, 7.2-11.4 months), and median overall survival was 26.2 months (95% CI, 21.9-30.4 months). Mild adverse events were observed in some participants, with few patients exhibiting grade 3 or greater adverse events. Low-dose erlotinib treatment was temporarily suspended for 10 patients owing to adverse events. Five of 80 patients (6%) had their erlotinib dose reduced to 25 mg because of oral mucositis, paronychia, erythema multiforme, diarrhea, and anorexia. Two patients discontinued treatment because of adverse events (cutaneous ulcer and bone infection, and oral mucositis, respectively). There were no cases of interstitial lung disease or treatment-related deaths. The median (range) erlotinib plasma concentration was measured at 685 (153-1950) ng/mL. Seventy-three patients discontinued study treatment owing to disease progression (n = 60), death (n = 3), AEs (n = 4), and patient requests (n = 6). No clear association was observed between the pharmacokinetics of low-dose erlotinib and the treatment outcome. Conclusions and Relevance Low-dose erlotinib appears to be safe and effective in elderly or frail patients with EGFR mutation-positive non-small cell lung cancer and can be a valid treatment option. Trial Registration UMIN-CTR Identifier: UMIN000015949.
Collapse
Affiliation(s)
- Shingo Miyamoto
- Department of Medical Oncology, Japanese Red Cross Medical Center, Tokyo, Japan
| | - Koichi Azuma
- Division of Respirology, Neurology, and Rheumatology, Department of Internal Medicine, Kurume University School of Medicine, Kurume, Japan
| | - Hidenobu Ishii
- Division of Respirology, Neurology, and Rheumatology, Department of Internal Medicine, Kurume University School of Medicine, Kurume, Japan
| | - Akihiro Bessho
- Department of Respiratory Medicine, Japanese Red Cross Okayama Hospital, Okayama, Japan
| | - Shinobu Hosokawa
- Department of Respiratory Medicine, Japanese Red Cross Okayama Hospital, Okayama, Japan
| | - Nobuaki Fukamatsu
- Department of Respiratory Medicine, Japanese Red Cross Okayama Hospital, Okayama, Japan
| | - Hideo Kunitoh
- Department of Medical Oncology, Japanese Red Cross Medical Center, Tokyo, Japan
| | - Mari Ishii
- Department of Respiratory Medicine and Medical Oncology, Yokohama Municipal Citizen's Hospital, Yokohama, Japan
| | - Hiroshi Tanaka
- Department of Internal Medicine, Niigata Cancer Center Hospital, Niigata, Japan
| | - Hiromi Aono
- Respiratory Medicine, Mitsui Memorial Hospital, Tokyo, Japan
| | - Yoshiro Nakahara
- Department of Respiratory Medicine, Kitasato University School of Medicine, Sagamihara, Japan
| | - Kei Kusaka
- The Center for Pulmonary Diseases, National Hospital Organization Tokyo National Hospital, Tokyo, Japan
| | - Yukio Hosomi
- Department of Respiratory Medicine, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan
| | - Norihiro Kikuchi
- Department of Respiratory Medicine, Kasumigaura Medical Center, Tsuchiura, Japan
| | - Yoshiaki Mori
- Department of Respiratory Medicine, Iwate Prefectural Central Hospital, Morioka, Japan
| | - Hidetoshi Itani
- Department of Respiratory Medicine, Japanese Red Cross Ise Hospital, Ise, Japan
| | - Akinobu Hamada
- Division of Molecular Pharmacology, National Cancer Center Research Institute, Tokyo, Japan
| | - Kazuhiko Yamada
- Division of Respirology, Neurology, and Rheumatology, Department of Internal Medicine, Kurume University School of Medicine, Kurume, Japan
| | - Hiroaki Okamoto
- Department of Respiratory Medicine and Medical Oncology, Yokohama Municipal Citizen's Hospital, Yokohama, Japan
| |
Collapse
|
9
|
Tang TL, Uesaka T, Kawase S, Beaumel D, Dozono M, Fujii T, Fukuda N, Fukunaga T, Galindo-Uribarri A, Hwang SH, Inabe N, Kameda D, Kawahara T, Kim W, Kisamori K, Kobayashi M, Kubo T, Kubota Y, Kusaka K, Lee CS, Maeda Y, Matsubara H, Michimasa S, Miya H, Noro T, Obertelli A, Ogata K, Ota S, Padilla-Rodal E, Sakaguchi S, Sakai H, Sasano M, Shimoura S, Stepanyan SS, Suzuki H, Takaki M, Takeda H, Tokieda H, Wakasa T, Wakui T, Yako K, Yanagisawa Y, Yasuda J, Yokoyama R, Yoshida K, Yoshida K, Zenihiro J. How Different is the Core of ^{25}F from ^{24}O_{g.s.} ? Phys Rev Lett 2020; 124:212502. [PMID: 32530645 DOI: 10.1103/physrevlett.124.212502] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/25/2018] [Revised: 12/15/2019] [Accepted: 04/13/2020] [Indexed: 06/11/2023]
Abstract
The structure of a neutron-rich ^{25}F nucleus is investigated by a quasifree (p,2p) knockout reaction at 270A MeV in inverse kinematics. The sum of spectroscopic factors of π0d_{5/2} orbital is found to be 1.0±0.3. However, the spectroscopic factor with residual ^{24}O nucleus being in the ground state is found to be only 0.36±0.13, while those in the excited state is 0.65±0.25. The result shows that the ^{24}O core of ^{25}F nucleus significantly differs from a free ^{24}O nucleus, and the core consists of ∼35% ^{24}O_{g.s.}. and ∼65% excited ^{24}O. The result may infer that the addition of the 0d_{5/2} proton considerably changes neutron structure in ^{25}F from that in ^{24}O, which could be a possible mechanism responsible for the oxygen dripline anomaly.
Collapse
Affiliation(s)
- T L Tang
- Center for Nuclear Study, University of Tokyo, 7-3-1 Hongo, Bunkyo, Tokyo 113-0033, Japan
- RIKEN Nishina Center, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - T Uesaka
- RIKEN Nishina Center, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - S Kawase
- Center for Nuclear Study, University of Tokyo, 7-3-1 Hongo, Bunkyo, Tokyo 113-0033, Japan
| | - D Beaumel
- Institut de physique nucléaire d'Orsay, 91406 Orsay, France
| | - M Dozono
- RIKEN Nishina Center, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - T Fujii
- Center for Nuclear Study, University of Tokyo, 7-3-1 Hongo, Bunkyo, Tokyo 113-0033, Japan
| | - N Fukuda
- RIKEN Nishina Center, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - T Fukunaga
- Kyushu University, 6-10-1 Hakozaki, Higashi, Fukuoka 812-8581, Japan
| | - A Galindo-Uribarri
- Oak Ridge National Laboratory, 1 Bethel Valley Rd, Oak Ridge, Tennessee 37831, USA
| | - S H Hwang
- Kyungpook National University, 80 Daehakro, Bukgu, Daegu 41566, Republic of Korea
| | - N Inabe
- RIKEN Nishina Center, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - D Kameda
- RIKEN Nishina Center, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - T Kawahara
- Toho University, 2-2-1 Miyama, Funabashi-shi, Chiba 274-8510, Japan
| | - W Kim
- Kyungpook National University, 80 Daehakro, Bukgu, Daegu 41566, Republic of Korea
| | - K Kisamori
- Center for Nuclear Study, University of Tokyo, 7-3-1 Hongo, Bunkyo, Tokyo 113-0033, Japan
| | - M Kobayashi
- Center for Nuclear Study, University of Tokyo, 7-3-1 Hongo, Bunkyo, Tokyo 113-0033, Japan
| | - T Kubo
- RIKEN Nishina Center, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - Y Kubota
- Center for Nuclear Study, University of Tokyo, 7-3-1 Hongo, Bunkyo, Tokyo 113-0033, Japan
| | - K Kusaka
- RIKEN Nishina Center, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - C S Lee
- Center for Nuclear Study, University of Tokyo, 7-3-1 Hongo, Bunkyo, Tokyo 113-0033, Japan
| | - Y Maeda
- University of Miyazaki, 1-1 Gakuen Kibanadai-nishi, Miyazaki 889-2192, Japan
| | - H Matsubara
- RIKEN Nishina Center, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - S Michimasa
- Center for Nuclear Study, University of Tokyo, 7-3-1 Hongo, Bunkyo, Tokyo 113-0033, Japan
| | - H Miya
- Center for Nuclear Study, University of Tokyo, 7-3-1 Hongo, Bunkyo, Tokyo 113-0033, Japan
| | - T Noro
- Kyushu University, 6-10-1 Hakozaki, Higashi, Fukuoka 812-8581, Japan
| | - A Obertelli
- RIKEN Nishina Center, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
- IRFU, CEA, Université Paris-Saclay, 91191 Gif-sur-Yvette, France
| | - K Ogata
- RCNP, Osaka University, 10-1 Mihogaoka, Ibaraki, Osaka 567-0047, Japan
- Department of Physics, Osaka City University, Osaka 558-8585, Japan
| | - S Ota
- Center for Nuclear Study, University of Tokyo, 7-3-1 Hongo, Bunkyo, Tokyo 113-0033, Japan
| | - E Padilla-Rodal
- Universidad Nacional Autónoma de México, Instituto de Ciencias Nucleares, AP 70-543, México City 04510, DF, México
| | - S Sakaguchi
- Kyushu University, 6-10-1 Hakozaki, Higashi, Fukuoka 812-8581, Japan
| | - H Sakai
- RIKEN Nishina Center, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - M Sasano
- RIKEN Nishina Center, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - S Shimoura
- Center for Nuclear Study, University of Tokyo, 7-3-1 Hongo, Bunkyo, Tokyo 113-0033, Japan
| | - S S Stepanyan
- Kyungpook National University, 80 Daehakro, Bukgu, Daegu 41566, Republic of Korea
| | - H Suzuki
- RIKEN Nishina Center, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - M Takaki
- Center for Nuclear Study, University of Tokyo, 7-3-1 Hongo, Bunkyo, Tokyo 113-0033, Japan
| | - H Takeda
- RIKEN Nishina Center, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - H Tokieda
- Center for Nuclear Study, University of Tokyo, 7-3-1 Hongo, Bunkyo, Tokyo 113-0033, Japan
| | - T Wakasa
- Kyushu University, 6-10-1 Hakozaki, Higashi, Fukuoka 812-8581, Japan
| | - T Wakui
- CYRIC, Tohoku University, 6-3 Aoba, Aramaki, Aoba-ku, Sendai, Miyagi 980-8578, Japan
| | - K Yako
- Center for Nuclear Study, University of Tokyo, 7-3-1 Hongo, Bunkyo, Tokyo 113-0033, Japan
| | - Y Yanagisawa
- RIKEN Nishina Center, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - J Yasuda
- Kyushu University, 6-10-1 Hakozaki, Higashi, Fukuoka 812-8581, Japan
| | - R Yokoyama
- Center for Nuclear Study, University of Tokyo, 7-3-1 Hongo, Bunkyo, Tokyo 113-0033, Japan
| | - K Yoshida
- RIKEN Nishina Center, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - K Yoshida
- RCNP, Osaka University, 10-1 Mihogaoka, Ibaraki, Osaka 567-0047, Japan
| | - J Zenihiro
- RIKEN Nishina Center, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| |
Collapse
|
10
|
Tanaka M, Takechi M, Homma A, Fukuda M, Nishimura D, Suzuki T, Tanaka Y, Moriguchi T, Ahn DS, Aimaganbetov A, Amano M, Arakawa H, Bagchi S, Behr KH, Burtebayev N, Chikaato K, Du H, Ebata S, Fujii T, Fukuda N, Geissel H, Hori T, Horiuchi W, Hoshino S, Igosawa R, Ikeda A, Inabe N, Inomata K, Itahashi K, Izumikawa T, Kamioka D, Kanda N, Kato I, Kenzhina I, Korkulu Z, Kuk Y, Kusaka K, Matsuta K, Mihara M, Miyata E, Nagae D, Nakamura S, Nassurlla M, Nishimuro K, Nishizuka K, Ohnishi K, Ohtake M, Ohtsubo T, Omika S, Ong HJ, Ozawa A, Prochazka A, Sakurai H, Scheidenberger C, Shimizu Y, Sugihara T, Sumikama T, Suzuki H, Suzuki S, Takeda H, Tanaka YK, Tanihata I, Wada T, Wakayama K, Yagi S, Yamaguchi T, Yanagihara R, Yanagisawa Y, Yoshida K, Zholdybayev TK. Swelling of Doubly Magic ^{48}Ca Core in Ca Isotopes beyond N=28. Phys Rev Lett 2020; 124:102501. [PMID: 32216444 DOI: 10.1103/physrevlett.124.102501] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/18/2019] [Revised: 12/20/2019] [Accepted: 01/30/2020] [Indexed: 06/10/2023]
Abstract
Interaction cross sections for ^{42-51}Ca on a carbon target at 280 MeV/nucleon have been measured for the first time. The neutron number dependence of derived root-mean-square matter radii shows a significant increase beyond the neutron magic number N=28. Furthermore, this enhancement of matter radii is much larger than that of the previously measured charge radii, indicating a novel growth in neutron skin thickness. A simple examination based on the Fermi-type distribution, and mean field calculations point out that this anomalous enhancement of the nuclear size beyond N=28 results from an enlargement of the core by a sudden increase in the surface diffuseness of the neutron density distribution, which implies the swelling of the bare ^{48}Ca core in Ca isotopes beyond N=28.
Collapse
Affiliation(s)
- M Tanaka
- Department of Physics, Osaka University, Toyonaka, Osaka 560-0043, Japan
- Research Center for Superheavy Elements, Kyushu University, Fukuoka 819-0395, Japan
| | - M Takechi
- Department of Physics, Niigata University, Ikarashi, Niigata 951-2181, Japan
| | - A Homma
- Department of Physics, Niigata University, Ikarashi, Niigata 951-2181, Japan
| | - M Fukuda
- Department of Physics, Osaka University, Toyonaka, Osaka 560-0043, Japan
| | - D Nishimura
- Department of Physics, Tokyo City University, Setagaya, Tokyo 158-8557, Japan
| | - T Suzuki
- Department of Physics, Saitama University, Saitama 338-8570, Japan
| | - Y Tanaka
- Department of Physics, Osaka University, Toyonaka, Osaka 560-0043, Japan
| | - T Moriguchi
- Institute of Physics, University of Tsukuba, Tsukuba, Ibaraki 305-8571, Japan
| | - D S Ahn
- RIKEN Nishina Center, Wako, Saitama 351-0198, Japan
| | - A Aimaganbetov
- Institute of Nuclear Physics, 050032 Almaty, Kazakhstan
- L.N. Gumilyov Eurasian National University, 010008 Astana, Kazakhstan
| | - M Amano
- Institute of Physics, University of Tsukuba, Tsukuba, Ibaraki 305-8571, Japan
| | - H Arakawa
- Department of Physics, Saitama University, Saitama 338-8570, Japan
| | - S Bagchi
- Astronomy and Physics Department, Saint Mary's University, Halifax, Nova Scotia B3H 3C3, Canada
- Justus Liebig University, 35392 Giessen, Germany
- GSI Helmholtzzentrum für Schwerionenforschung, 64291 Darmstadt, Germany
| | - K-H Behr
- GSI Helmholtzzentrum für Schwerionenforschung, 64291 Darmstadt, Germany
| | - N Burtebayev
- Institute of Nuclear Physics, 050032 Almaty, Kazakhstan
| | - K Chikaato
- Department of Physics, Niigata University, Ikarashi, Niigata 951-2181, Japan
| | - H Du
- Department of Physics, Osaka University, Toyonaka, Osaka 560-0043, Japan
| | - S Ebata
- Department of Physics, Saitama University, Saitama 338-8570, Japan
- School of Environment and Society, Tokyo Institute of Technology, Meguro, Tokyo 152-8551, Japan
| | - T Fujii
- Department of Physics, Saitama University, Saitama 338-8570, Japan
| | - N Fukuda
- RIKEN Nishina Center, Wako, Saitama 351-0198, Japan
| | - H Geissel
- GSI Helmholtzzentrum für Schwerionenforschung, 64291 Darmstadt, Germany
| | - T Hori
- Department of Physics, Osaka University, Toyonaka, Osaka 560-0043, Japan
| | - W Horiuchi
- Department of Physics, Hokkaido University, Sapporo 060-0810, Japan
| | - S Hoshino
- Department of Physics, Niigata University, Ikarashi, Niigata 951-2181, Japan
| | - R Igosawa
- Department of Physics, Saitama University, Saitama 338-8570, Japan
| | - A Ikeda
- Department of Physics, Niigata University, Ikarashi, Niigata 951-2181, Japan
| | - N Inabe
- RIKEN Nishina Center, Wako, Saitama 351-0198, Japan
| | - K Inomata
- Department of Physics, Saitama University, Saitama 338-8570, Japan
| | - K Itahashi
- RIKEN Nishina Center, Wako, Saitama 351-0198, Japan
| | - T Izumikawa
- Institute for Research Promotion, Niigata University, Niigata 950-8510, Japan
| | - D Kamioka
- Institute of Physics, University of Tsukuba, Tsukuba, Ibaraki 305-8571, Japan
| | - N Kanda
- Department of Physics, Niigata University, Ikarashi, Niigata 951-2181, Japan
| | - I Kato
- Department of Physics, Saitama University, Saitama 338-8570, Japan
| | - I Kenzhina
- Institute of Nuclear Physics, 050032 Almaty, Kazakhstan
- Al-Farabi Kazakh National University, 050040 Almaty, Kazakhstan
| | - Z Korkulu
- RIKEN Nishina Center, Wako, Saitama 351-0198, Japan
| | - Y Kuk
- Institute of Nuclear Physics, 050032 Almaty, Kazakhstan
- L.N. Gumilyov Eurasian National University, 010008 Astana, Kazakhstan
| | - K Kusaka
- RIKEN Nishina Center, Wako, Saitama 351-0198, Japan
| | - K Matsuta
- Department of Physics, Osaka University, Toyonaka, Osaka 560-0043, Japan
| | - M Mihara
- Department of Physics, Osaka University, Toyonaka, Osaka 560-0043, Japan
| | - E Miyata
- Department of Physics, Niigata University, Ikarashi, Niigata 951-2181, Japan
| | - D Nagae
- Research Center for Superheavy Elements, Kyushu University, Fukuoka 819-0395, Japan
- RIKEN Nishina Center, Wako, Saitama 351-0198, Japan
| | - S Nakamura
- Department of Physics, Osaka University, Toyonaka, Osaka 560-0043, Japan
| | - M Nassurlla
- Institute of Nuclear Physics, 050032 Almaty, Kazakhstan
- Al-Farabi Kazakh National University, 050040 Almaty, Kazakhstan
| | - K Nishimuro
- Department of Physics, Saitama University, Saitama 338-8570, Japan
| | - K Nishizuka
- Department of Physics, Niigata University, Ikarashi, Niigata 951-2181, Japan
| | - K Ohnishi
- Department of Physics, Osaka University, Toyonaka, Osaka 560-0043, Japan
| | - M Ohtake
- RIKEN Nishina Center, Wako, Saitama 351-0198, Japan
| | - T Ohtsubo
- Department of Physics, Niigata University, Ikarashi, Niigata 951-2181, Japan
| | - S Omika
- Department of Physics, Saitama University, Saitama 338-8570, Japan
| | - H J Ong
- Research Center for Nuclear Physics, Osaka University, Ibaraki, Osaka 567-0047, Japan
| | - A Ozawa
- Institute of Physics, University of Tsukuba, Tsukuba, Ibaraki 305-8571, Japan
| | - A Prochazka
- GSI Helmholtzzentrum für Schwerionenforschung, 64291 Darmstadt, Germany
| | - H Sakurai
- RIKEN Nishina Center, Wako, Saitama 351-0198, Japan
- Department of Physics, University of Tokyo, Bunkyo-ku, Tokyo 113-0033, Japan
| | - C Scheidenberger
- GSI Helmholtzzentrum für Schwerionenforschung, 64291 Darmstadt, Germany
| | - Y Shimizu
- RIKEN Nishina Center, Wako, Saitama 351-0198, Japan
| | - T Sugihara
- Department of Physics, Osaka University, Toyonaka, Osaka 560-0043, Japan
| | - T Sumikama
- RIKEN Nishina Center, Wako, Saitama 351-0198, Japan
| | - H Suzuki
- RIKEN Nishina Center, Wako, Saitama 351-0198, Japan
| | - S Suzuki
- Institute of Physics, University of Tsukuba, Tsukuba, Ibaraki 305-8571, Japan
| | - H Takeda
- RIKEN Nishina Center, Wako, Saitama 351-0198, Japan
| | - Y K Tanaka
- GSI Helmholtzzentrum für Schwerionenforschung, 64291 Darmstadt, Germany
| | - I Tanihata
- Research Center for Nuclear Physics, Osaka University, Ibaraki, Osaka 567-0047, Japan
- School of Physics and Nuclear Energy Engineering, Beihang University, 100191 Beijing, China
| | - T Wada
- Department of Physics, Niigata University, Ikarashi, Niigata 951-2181, Japan
| | - K Wakayama
- Department of Physics, Saitama University, Saitama 338-8570, Japan
| | - S Yagi
- Department of Physics, Osaka University, Toyonaka, Osaka 560-0043, Japan
| | - T Yamaguchi
- Department of Physics, Saitama University, Saitama 338-8570, Japan
- Tomonaga Center for the History of the Universe, University of Tsukuba, Ibaraki 305-8571, Japan
| | - R Yanagihara
- Department of Physics, Osaka University, Toyonaka, Osaka 560-0043, Japan
| | - Y Yanagisawa
- RIKEN Nishina Center, Wako, Saitama 351-0198, Japan
| | - K Yoshida
- RIKEN Nishina Center, Wako, Saitama 351-0198, Japan
| | - T K Zholdybayev
- Institute of Nuclear Physics, 050032 Almaty, Kazakhstan
- Al-Farabi Kazakh National University, 050040 Almaty, Kazakhstan
| |
Collapse
|
11
|
Ahn DS, Fukuda N, Geissel H, Inabe N, Iwasa N, Kubo T, Kusaka K, Morrissey DJ, Murai D, Nakamura T, Ohtake M, Otsu H, Sato H, Sherrill BM, Shimizu Y, Suzuki H, Takeda H, Tarasov OB, Ueno H, Yanagisawa Y, Yoshida K. Location of the Neutron Dripline at Fluorine and Neon. Phys Rev Lett 2019; 123:212501. [PMID: 31809143 DOI: 10.1103/physrevlett.123.212501] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/28/2019] [Indexed: 06/10/2023]
Abstract
A search for the heaviest isotopes of fluorine, neon, and sodium was conducted by fragmentation of an intense ^{48}Ca beam at 345 MeV/nucleon with a 20-mm-thick beryllium target and identification of isotopes in the large-acceptance separator BigRIPS at the RIKEN Radioactive Isotope Beam Factory. No events were observed for ^{32,33}F, ^{35,36}Ne, and ^{38}Na and only one event for ^{39}Na after extensive running. Comparison with predicted yields excludes the existence of bound states of these unobserved isotopes with high confidence levels. The present work indicates that ^{31}F and ^{34}Ne are the heaviest bound isotopes of fluorine and neon, respectively. The neutron dripline has thus been experimentally confirmed up to neon for the first time since ^{24}O was confirmed to be the dripline nucleus nearly 20 years ago. These data provide new keys to understanding the nuclear stability at extremely neutron-rich conditions.
Collapse
Affiliation(s)
- D S Ahn
- RIKEN Nishina Center for Accelerator-Based Science, RIKEN, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - N Fukuda
- RIKEN Nishina Center for Accelerator-Based Science, RIKEN, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - H Geissel
- GSI, Helmholtzzentrum für Schwerionenforschung GmbH, Planckstraße 1, 64291 Darmstadt, Germany
| | - N Inabe
- RIKEN Nishina Center for Accelerator-Based Science, RIKEN, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - N Iwasa
- Department of Physics, Tohoku University, 6-3, Aramaki Aza-Aoba, Aoba-ku, Sendai, Miyagi 980-8578, Japan
| | - T Kubo
- RIKEN Nishina Center for Accelerator-Based Science, RIKEN, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - K Kusaka
- RIKEN Nishina Center for Accelerator-Based Science, RIKEN, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - D J Morrissey
- National Superconducting Cyclotron Laboratory, Michigan State University, 640 South Shaw Lane, East Lansing, Michigan 48824, USA
| | - D Murai
- Department of Physics, Rikkyo University, 3-34-1 Nishi-Ikebukuro, Toshima, Tokyo 171-8501, Japan
| | - T Nakamura
- Department of Physics, Tokyo Institute of Technology, 2-12-1 O-Okayama, Meguro, Tokyo 152-8551, Japan
| | - M Ohtake
- RIKEN Nishina Center for Accelerator-Based Science, RIKEN, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - H Otsu
- RIKEN Nishina Center for Accelerator-Based Science, RIKEN, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - H Sato
- RIKEN Nishina Center for Accelerator-Based Science, RIKEN, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - B M Sherrill
- National Superconducting Cyclotron Laboratory, Michigan State University, 640 South Shaw Lane, East Lansing, Michigan 48824, USA
| | - Y Shimizu
- RIKEN Nishina Center for Accelerator-Based Science, RIKEN, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - H Suzuki
- RIKEN Nishina Center for Accelerator-Based Science, RIKEN, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - H Takeda
- RIKEN Nishina Center for Accelerator-Based Science, RIKEN, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - O B Tarasov
- National Superconducting Cyclotron Laboratory, Michigan State University, 640 South Shaw Lane, East Lansing, Michigan 48824, USA
| | - H Ueno
- RIKEN Nishina Center for Accelerator-Based Science, RIKEN, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - Y Yanagisawa
- RIKEN Nishina Center for Accelerator-Based Science, RIKEN, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - K Yoshida
- RIKEN Nishina Center for Accelerator-Based Science, RIKEN, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| |
Collapse
|
12
|
Kusaka K, Tamura A, Kozuki T, Koreeda Y, Kita T, Endo T, Shibayama T, Hatakeyama N, Miura M, Yamashita N, Takenoyama M. Randomized trial of prophylactic minocycline for erlotinib-associated skin rash in non-small cell lung cancer (PEARL trial). Ann Oncol 2019. [DOI: 10.1093/annonc/mdz437.014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
13
|
Otani S, Yamada K, Miyamoto S, Azuma K, Ishii H, Bessho A, Hosokawa S, Kunitoh H, Miyazaki K, Tanaka H, Miura S, Aono H, Nakahara Y, Kusaka K, Hosomi Y, Hamada A, Okamoto H. MA21.11 A Multicenter Phase II Study of Low-Dose Erlotinib in Frail Patients with EGFR Mutation-Positive, Non-Small Cell Lung Cancer: TORG1425. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.681] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
14
|
Bessho A, Miyamoto S, Azuma K, Ishii H, Hosokawa S, Kunitoh H, Shimokawa T, Tanaka H, Aono H, Nakahara Y, Hosomi Y, Kusaka K, Yamada K, Okamoto H. A phase II study of low-dose erlotinib in frail patients with EGFR-mutant non-small cell lung cancer: TORG1425. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy374.034] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
15
|
Miyamoto S, Tokkito T, Bessho A, Fukamatsu N, Kunitoh H, Ishii M, Tanaka H, Aono H, Fukui T, Kusaka K, Hosomi Y, Hamada A, Yamada K, Okamoto H. ABCB1 genetic polymorphism and pharmacokinetic analysis of low dose erlotinib in frail patients with EGFR mutation (mt)-positive, non-small cell lung cancer: TORG1425. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy292.047] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
16
|
Yokoyama A, Tamura A, Miyakawa K, Kusaka K, Shimada M, Hirose T, Matsui H, Kitani M, Hebisawa A, Ohta K. Pulmonary Adenocarcinoma, Harboring Both an EGFR Mutation and ALK Rearrangement, Presenting a Stable Disease to Erlotinib and a Partial Response to Alectinib. Intern Med 2018; 57. [PMID: 29526950 PMCID: PMC6148164 DOI: 10.2169/internalmedicine.0383-17] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
A 63-year-old woman with pulmonary adenocarcinoma (stage IIIB) that was positive for an epidermal growth factor receptor (EGFR) mutation and an anaplastic lymphoma kinase (ALK) rearrangement was treated with erlotinib as the first-line treatment, resulting in a stable disease. Due to skin rashes, fatigue and anorexia, erlotinib was suspended on erlotinib day 44. Alectinib was administered as the second-line treatment, exhibiting a partial response. On alectinib day 56, drug-induced lung injury forced suspension of alectinib, which was cured with corticosteroid therapy. ALK-tyrosine kinase inhibitors may be more effective for patients positive for both EGFR mutation and ALK rearrangement than other agents.
Collapse
Affiliation(s)
- Akira Yokoyama
- Center for Pulmonary Diseases, National Hospital Organization Tokyo National Hospital, Japan
- Department of Respiratory Medicine, Graduated School of Medicine, The University of Tokyo, Japan
| | - Atsuhisa Tamura
- Center for Pulmonary Diseases, National Hospital Organization Tokyo National Hospital, Japan
| | - Kazuko Miyakawa
- Center for Pulmonary Diseases, National Hospital Organization Tokyo National Hospital, Japan
| | - Kei Kusaka
- Center for Pulmonary Diseases, National Hospital Organization Tokyo National Hospital, Japan
| | - Masahiro Shimada
- Center for Pulmonary Diseases, National Hospital Organization Tokyo National Hospital, Japan
| | - Takashi Hirose
- Center for Pulmonary Diseases, National Hospital Organization Tokyo National Hospital, Japan
| | - Hirotoshi Matsui
- Center for Pulmonary Diseases, National Hospital Organization Tokyo National Hospital, Japan
| | - Masashi Kitani
- Department of Pathology, National Hospital Organization Tokyo National Hospital, Japan
| | - Akira Hebisawa
- Department of Pathology, National Hospital Organization Tokyo National Hospital, Japan
| | - Ken Ohta
- Center for Pulmonary Diseases, National Hospital Organization Tokyo National Hospital, Japan
| |
Collapse
|
17
|
Shimada M, Tamura A, Yokosuka K, Kusaka K, Matsui H, Nagai H, Ohta K. A successful pembrolizumab treatment case of lung adenocarcinoma after becoming resistant to ALK-TKI treatment due to G1202R mutation. Respir Investig 2018; 56:365-368. [PMID: 30008296 DOI: 10.1016/j.resinv.2018.04.004] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/25/2017] [Revised: 04/11/2018] [Accepted: 04/25/2018] [Indexed: 10/28/2022]
Abstract
BACKGROUND In current guidelines, the role of immune checkpoint inhibitors is not yet determined in the treatment strategy for NSCLC harboring ALK translocations. CASE A 51-year-old woman with lung adenocarcinoma harboring ALK translocation was treated with alectinib until PD. After the second (CDDP/PEM) and third (crizotinib) line treatment, a second biopsy was performed, revealing PD-L1 tumor proportion score of 70-80% and G1202R mutation of ALK. Pembrolizumab was selected for the fourth line, leading to PR for more than 6 months. CONCLUSIONS While alectinib might induce resistance to ALK-TKI, it could increase PD-L1 positive cells to become sensitive to PD-1/PD-L1 inhibitors.
Collapse
Affiliation(s)
- Masahiro Shimada
- Center for Pulmonary Diseases, National Hospital Organization Tokyo National Hospital, 3-1-1 Takeoka, Kiyose, Tokyo 204-8585, Japan.
| | - Atsuhisa Tamura
- Center for Pulmonary Diseases, National Hospital Organization Tokyo National Hospital, 3-1-1 Takeoka, Kiyose, Tokyo 204-8585, Japan.
| | - Kyoko Yokosuka
- Center for Pulmonary Diseases, National Hospital Organization Tokyo National Hospital, 3-1-1 Takeoka, Kiyose, Tokyo 204-8585, Japan.
| | - Kei Kusaka
- Center for Pulmonary Diseases, National Hospital Organization Tokyo National Hospital, 3-1-1 Takeoka, Kiyose, Tokyo 204-8585, Japan.
| | - Hirotoshi Matsui
- Center for Pulmonary Diseases, National Hospital Organization Tokyo National Hospital, 3-1-1 Takeoka, Kiyose, Tokyo 204-8585, Japan.
| | - Hideaki Nagai
- Center for Pulmonary Diseases, National Hospital Organization Tokyo National Hospital, 3-1-1 Takeoka, Kiyose, Tokyo 204-8585, Japan.
| | - Ken Ohta
- Center for Pulmonary Diseases, National Hospital Organization Tokyo National Hospital, 3-1-1 Takeoka, Kiyose, Tokyo 204-8585, Japan.
| |
Collapse
|
18
|
Tarasov OB, Ahn DS, Bazin D, Fukuda N, Gade A, Hausmann M, Inabe N, Ishikawa S, Iwasa N, Kawata K, Komatsubara T, Kubo T, Kusaka K, Morrissey DJ, Ohtake M, Otsu H, Portillo M, Sakakibara T, Sakurai H, Sato H, Sherrill BM, Shimizu Y, Stolz A, Sumikama T, Suzuki H, Takeda H, Thoennessen M, Ueno H, Yanagisawa Y, Yoshida K. Discovery of ^{60}Ca and Implications For the Stability of ^{70}Ca. Phys Rev Lett 2018; 121:022501. [PMID: 30085743 DOI: 10.1103/physrevlett.121.022501] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/07/2018] [Revised: 06/11/2018] [Indexed: 06/08/2023]
Abstract
The discovery of the important neutron-rich nucleus _{20}^{60}Ca_{40} and seven others near the limits of nuclear stability is reported from the fragmentation of a 345 MeV/u ^{70}Zn projectile beam on ^{9}Be targets at the radioactive ion-beam factory of the RIKEN Nishina Center. The produced fragments were analyzed and unambiguously identified using the BigRIPS two-stage in-flight separator. The eight new neutron-rich nuclei discovered, ^{47}P, ^{49}S, ^{52}Cl, ^{54}Ar, ^{57}K, ^{59,60}Ca, and ^{62}Sc, are the most neutron-rich isotopes of the respective elements. In addition, one event consistent with ^{59}K was registered. The results are compared with the drip lines predicted by a variety of mass models and it is found that the models in best agreement with the observed limits of existence in the explored region tend to predict the even-mass Ca isotopes to be bound out to at least ^{70}Ca.
Collapse
Affiliation(s)
- O B Tarasov
- National Superconducting Cyclotron Laboratory, Michigan State University, East Lansing, Michigan 48824, USA
- RIKEN Nishina Center, RIKEN, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
- Flerov Laboratory of Nuclear Reactions, JINR, 141980 Dubna, Moscow Region, Russian Federation
| | - D S Ahn
- RIKEN Nishina Center, RIKEN, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - D Bazin
- National Superconducting Cyclotron Laboratory, Michigan State University, East Lansing, Michigan 48824, USA
| | - N Fukuda
- RIKEN Nishina Center, RIKEN, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - A Gade
- National Superconducting Cyclotron Laboratory, Michigan State University, East Lansing, Michigan 48824, USA
- Department of Physics and Astronomy, Michigan State University, East Lansing, Michigan 48824, USA
| | - M Hausmann
- Facility for Rare Isotope Beams, Michigan State University, East Lansing, Michigan 48824, USA
| | - N Inabe
- RIKEN Nishina Center, RIKEN, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - S Ishikawa
- Department of Physics, Tohoku University, 6-3 Aramaki-aza-aoba, Aoba, Sendai 980-8578, Japan
| | - N Iwasa
- Department of Physics, Tohoku University, 6-3 Aramaki-aza-aoba, Aoba, Sendai 980-8578, Japan
| | - K Kawata
- Center for Nuclear Study, University of Tokyo, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - T Komatsubara
- RIKEN Nishina Center, RIKEN, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - T Kubo
- Facility for Rare Isotope Beams, Michigan State University, East Lansing, Michigan 48824, USA
| | - K Kusaka
- RIKEN Nishina Center, RIKEN, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - D J Morrissey
- National Superconducting Cyclotron Laboratory, Michigan State University, East Lansing, Michigan 48824, USA
- Department of Chemistry, Michigan State University, East Lansing, Michigan 48824, USA
| | - M Ohtake
- RIKEN Nishina Center, RIKEN, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - H Otsu
- RIKEN Nishina Center, RIKEN, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - M Portillo
- Facility for Rare Isotope Beams, Michigan State University, East Lansing, Michigan 48824, USA
| | - T Sakakibara
- Department of Physics, Tohoku University, 6-3 Aramaki-aza-aoba, Aoba, Sendai 980-8578, Japan
| | - H Sakurai
- RIKEN Nishina Center, RIKEN, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - H Sato
- RIKEN Nishina Center, RIKEN, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - B M Sherrill
- National Superconducting Cyclotron Laboratory, Michigan State University, East Lansing, Michigan 48824, USA
- Department of Physics and Astronomy, Michigan State University, East Lansing, Michigan 48824, USA
| | - Y Shimizu
- RIKEN Nishina Center, RIKEN, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - A Stolz
- National Superconducting Cyclotron Laboratory, Michigan State University, East Lansing, Michigan 48824, USA
| | - T Sumikama
- RIKEN Nishina Center, RIKEN, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - H Suzuki
- RIKEN Nishina Center, RIKEN, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - H Takeda
- RIKEN Nishina Center, RIKEN, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - M Thoennessen
- National Superconducting Cyclotron Laboratory, Michigan State University, East Lansing, Michigan 48824, USA
- Department of Physics and Astronomy, Michigan State University, East Lansing, Michigan 48824, USA
| | - H Ueno
- RIKEN Nishina Center, RIKEN, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - Y Yanagisawa
- RIKEN Nishina Center, RIKEN, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - K Yoshida
- RIKEN Nishina Center, RIKEN, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| |
Collapse
|
19
|
Yamada K, Miyamoto S, Azuma K, Ishii H, Bessho A, Fukamatsu N, Kunitoh H, Ishii M, Tanaka H, Aono H, Nakahara Y, Kusaka K, Hosomi Y, Kikuchi N, Mori Y, Itani H, Kasai T, Ichiki M, Seki N, Okamoto H. A multicenter phase II study of low-dose erlotinib in frail patients with EGFR mutation-positive, non-small cell lung cancer: Thoracic oncology research group (TORG) trial 1425. J Clin Oncol 2018. [DOI: 10.1200/jco.2018.36.15_suppl.9063] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- Kazuhiko Yamada
- Division of Respirology, Neurology, and Rheumatology, Department of Internal Medicine, Kurume University School of Medicine, Kurume, Japan
| | | | - Koichi Azuma
- Division of Respirology, Neurology, and Rheumatology, Department of Internal Medicine, Kurume University School of Medicine, Kurume, Japan
| | - Hidenobu Ishii
- Division of Respirology, Neurology, and Rheumatology, Department of Internal Medicine, Kurume University School of Medicine, Kurume, Japan
| | | | | | | | - Mari Ishii
- Yokohama Municipal Citizen's Hospital, Yokohama, Japan
| | - Hiroshi Tanaka
- Department of Respiratory Medicine, Niigata Cancer Center Hospital, Niigata, Japan
| | | | | | - Kei Kusaka
- National Hospital Organization Tokyo National Hospital, Tokyo, Japan
| | - Yukio Hosomi
- Department of Thoracic Oncology and Respiratory Medicine, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan
| | | | | | | | - Takashi Kasai
- Department of Respiratory Medicine, Tochigi Cancer Center, Utsunomiya, Japan
| | | | | | - Hiroaki Okamoto
- Department of Respiratory Medicine and Medical Oncology, Yokohama Municipal Citizen's Hospital, Yokohama, Japan
| |
Collapse
|
20
|
Nishi T, Itahashi K, Berg GPA, Fujioka H, Fukuda N, Fukunishi N, Geissel H, Hayano RS, Hirenzaki S, Ichikawa K, Ikeno N, Inabe N, Itoh S, Iwasaki M, Kameda D, Kawase S, Kubo T, Kusaka K, Matsubara H, Michimasa S, Miki K, Mishima G, Miya H, Nagahiro H, Nakamura M, Noji S, Okochi K, Ota S, Sakamoto N, Suzuki K, Takeda H, Tanaka YK, Todoroki K, Tsukada K, Uesaka T, Watanabe YN, Weick H, Yamakami H, Yoshida K. Spectroscopy of Pionic Atoms in ^{122}Sn(d,^{3}He) Reaction and Angular Dependence of the Formation Cross Sections. Phys Rev Lett 2018; 120:152505. [PMID: 29756883 DOI: 10.1103/physrevlett.120.152505] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/24/2017] [Revised: 02/07/2018] [Indexed: 06/08/2023]
Abstract
We observed the atomic 1s and 2p states of π^{-} bound to ^{121}Sn nuclei as distinct peak structures in the missing mass spectra of the ^{122}Sn(d,^{3}He) nuclear reaction. A very intense deuteron beam and a spectrometer with a large angular acceptance let us achieve a potential of discovery, which includes the capability of determining the angle-dependent cross sections with high statistics. The 2p state in a Sn nucleus was observed for the first time. The binding energies and widths of the pionic states are determined and found to be consistent with previous experimental results of other Sn isotopes. The spectrum is measured at finite reaction angles for the first time. The formation cross sections at the reaction angles between 0° and 2° are determined. The observed reaction-angle dependence of each state is reproduced by theoretical calculations. However, the quantitative comparison with our high-precision data reveals a significant discrepancy between the measured and calculated formation cross sections of the pionic 1s state.
Collapse
Affiliation(s)
- T Nishi
- Department of Physics, School of Science, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, 113-0033 Tokyo, Japan
- Nishina Center for Accelerator-Based Science, RIKEN, 2-1 Hirosawa, Wako, 351-0198 Saitama, Japan
| | - K Itahashi
- Nishina Center for Accelerator-Based Science, RIKEN, 2-1 Hirosawa, Wako, 351-0198 Saitama, Japan
| | - G P A Berg
- Department of Physics and the Joint Institute for Nuclear Astrophysics Center for the Evolution of the Elements, University of Notre Dame, Notre Dame, Indiana 46556, USA
| | - H Fujioka
- Department of Physics, Kyoto University, Kitashirakawa-Oiwakecho, Sakyo-ku, Kyoto, 606-8502 Kyoto, Japan
| | - N Fukuda
- Nishina Center for Accelerator-Based Science, RIKEN, 2-1 Hirosawa, Wako, 351-0198 Saitama, Japan
| | - N Fukunishi
- Nishina Center for Accelerator-Based Science, RIKEN, 2-1 Hirosawa, Wako, 351-0198 Saitama, Japan
| | - H Geissel
- GSI Helmholtzzentrum für Schwerionenforschung GmbH, Planckstrasse 1, D-64291 Darmstadt, Germany
| | - R S Hayano
- Department of Physics, School of Science, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, 113-0033 Tokyo, Japan
| | - S Hirenzaki
- Department of Physics, Nara Women's University, Kita-Uoya Nishimachi, Nara, 630-8506 Nara, Japan
| | - K Ichikawa
- Department of Physics, School of Science, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, 113-0033 Tokyo, Japan
| | - N Ikeno
- Department of Life and Environmental Agricultural Sciences, Faculty of Agriculture, Tottori University, 4-101 Koyamacho-Minami, Tottori, 680-8551 Tottori, Japan
| | - N Inabe
- Nishina Center for Accelerator-Based Science, RIKEN, 2-1 Hirosawa, Wako, 351-0198 Saitama, Japan
| | - S Itoh
- Department of Physics, School of Science, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, 113-0033 Tokyo, Japan
| | - M Iwasaki
- Nishina Center for Accelerator-Based Science, RIKEN, 2-1 Hirosawa, Wako, 351-0198 Saitama, Japan
| | - D Kameda
- Nishina Center for Accelerator-Based Science, RIKEN, 2-1 Hirosawa, Wako, 351-0198 Saitama, Japan
| | - S Kawase
- Center for Nuclear Study, The University of Tokyo, 2-1 Hirosawa, Wako, 351-0198 Saitama, Japan
| | - T Kubo
- Nishina Center for Accelerator-Based Science, RIKEN, 2-1 Hirosawa, Wako, 351-0198 Saitama, Japan
| | - K Kusaka
- Nishina Center for Accelerator-Based Science, RIKEN, 2-1 Hirosawa, Wako, 351-0198 Saitama, Japan
| | - H Matsubara
- Center for Nuclear Study, The University of Tokyo, 2-1 Hirosawa, Wako, 351-0198 Saitama, Japan
| | - S Michimasa
- Center for Nuclear Study, The University of Tokyo, 2-1 Hirosawa, Wako, 351-0198 Saitama, Japan
| | - K Miki
- Department of Physics, School of Science, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, 113-0033 Tokyo, Japan
| | - G Mishima
- Department of Physics, School of Science, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, 113-0033 Tokyo, Japan
| | - H Miya
- Nishina Center for Accelerator-Based Science, RIKEN, 2-1 Hirosawa, Wako, 351-0198 Saitama, Japan
| | - H Nagahiro
- Department of Physics, Nara Women's University, Kita-Uoya Nishimachi, Nara, 630-8506 Nara, Japan
| | - M Nakamura
- Nishina Center for Accelerator-Based Science, RIKEN, 2-1 Hirosawa, Wako, 351-0198 Saitama, Japan
| | - S Noji
- Department of Physics, School of Science, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, 113-0033 Tokyo, Japan
| | - K Okochi
- Department of Physics, School of Science, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, 113-0033 Tokyo, Japan
| | - S Ota
- Center for Nuclear Study, The University of Tokyo, 2-1 Hirosawa, Wako, 351-0198 Saitama, Japan
| | - N Sakamoto
- Nishina Center for Accelerator-Based Science, RIKEN, 2-1 Hirosawa, Wako, 351-0198 Saitama, Japan
| | - K Suzuki
- Stefan Meyer Institute for Subatomic Physics, Austrian Academy of Sciences, Boltzmanngasse 3, A-1090 Vienna, Austria
| | - H Takeda
- Nishina Center for Accelerator-Based Science, RIKEN, 2-1 Hirosawa, Wako, 351-0198 Saitama, Japan
| | - Y K Tanaka
- Department of Physics, School of Science, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, 113-0033 Tokyo, Japan
| | - K Todoroki
- Department of Physics, School of Science, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, 113-0033 Tokyo, Japan
| | - K Tsukada
- Nishina Center for Accelerator-Based Science, RIKEN, 2-1 Hirosawa, Wako, 351-0198 Saitama, Japan
| | - T Uesaka
- Nishina Center for Accelerator-Based Science, RIKEN, 2-1 Hirosawa, Wako, 351-0198 Saitama, Japan
| | - Y N Watanabe
- Department of Physics, School of Science, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, 113-0033 Tokyo, Japan
| | - H Weick
- GSI Helmholtzzentrum für Schwerionenforschung GmbH, Planckstrasse 1, D-64291 Darmstadt, Germany
| | - H Yamakami
- Department of Physics, Kyoto University, Kitashirakawa-Oiwakecho, Sakyo-ku, Kyoto, 606-8502 Kyoto, Japan
| | - K Yoshida
- Nishina Center for Accelerator-Based Science, RIKEN, 2-1 Hirosawa, Wako, 351-0198 Saitama, Japan
| |
Collapse
|
21
|
Iwanaga S, Kusaka K, Harano K, Satomura K. Analytical study on Japanese health education textbooks for junior high school students on HIV/AIDS. Eur J Public Health 2016. [DOI: 10.1093/eurpub/ckw175.132] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
22
|
Yu F, Takahashi T, Moriya J, Kawaura K, Yamakawa J, Kusaka K, Itoh T, Morimoto S, Yamaguchi N, Kanda T. Traditional Chinese Medicine and Kampo: A Review from the Distant past for the Future. J Int Med Res 2016; 34:231-9. [PMID: 16866016 DOI: 10.1177/147323000603400301] [Citation(s) in RCA: 154] [Impact Index Per Article: 19.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
Traditional Chinese medicine (TCM) is a complete system of healing that developed in China about 3000 years ago, and includes herbal medicine, acupuncture, moxibustion and massage, etc. In recent decades the use of TCM has become more popular in China and throughout the world. Traditional Japanese medicine has been used for 1500 years and includes Kampo-yaku (herbal medicine), acupuncture and acupressure. Kampo is now widely practised in Japan and is fully integrated into the modern health-care system. Kampo is based on TCM but has been adapted to Japanese culture. In this paper we review the history and characteristics of TCM and traditional Japanese medicine, i.e. the selection of traditional Chinese herbal medicine treatments based on differential diagnosis, and treatment formulations specific for the ‘Sho’ (the patient's symptoms at a given moment) of Japanese Kampo - and look at the prospects for these forms of medicine.
Collapse
Affiliation(s)
- F Yu
- Department of General Medicine, Kanazawa Medical University, Ishikawa, Japan
| | | | | | | | | | | | | | | | | | | |
Collapse
|
23
|
Mori A, Hirose T, Tamura A, Kusaka K, Matsui H, Ohta K. [Evaluation of the Efficacy and Safety of Platinum Doublet Re-Challenge Chemotherapy in Patients with Recurrent Advanced Non-Small Cell Lung Cancer]. Gan To Kagaku Ryoho 2016; 43:723-726. [PMID: 27306808] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Abstract
BACKGROUND Docetaxel or pemetrexed is the standard treatment for recurrent advanced non-small cell lung cancer (NSCLC). Until now, combination chemotherapy has failed to demonstrate superiority in patients with recurrent advanced NSCLC, compared to single-agent chemotherapy. The aim of the present study was to assess the efficacy and safety of platinum doublet re-challenge chemotherapy in patients with recurrent advanced NSCLC. METHODS Fifty-eight patients with recurrent advanced NSCLC who underwent platinum doublet re-challenge chemotherapy were retrospectively analyzed. RESULTS The response rate was 6.9%(95%CI: 1.9-16.7%), the disease control rate was 70.7% (95%CI: 57.3-81.9%), the median progression-free survival (PFS) was 123 days, and the median survival time (MST) after re-challenge chemotherapy was 470 days. The disease control rate and the PFS were significantly better in patients who achieved a partial response to first-line chemotherapy than in patients who had stable or progressive disease. In addition, the PFS and MST were significantly longer in patients whose treatment-free interval was more than 90 days. Toxicities were tolerable in most patients, except for 1 patient who showed drug-induced pneumonia. CONCLUSION Platinum doublet re-challenge chemotherapy is a treatment option for patients with advanced NSCLC who achieved a partial response to first-line chemotherapy or for patients whose treatment-free interval lasted longer than 90 days.
Collapse
Affiliation(s)
- Aya Mori
- Dept. of Respirology, National Hospital Organization Tokyo National Hospital
| | | | | | | | | | | |
Collapse
|
24
|
Tamura A, Hebisawa A, Kusaka K, Hirose T, Suzuki J, Yamane A, Nagai H, Fukami T, Ohta K, Takahashi F. Relationship Between Lung Cancer and Mycobacterium Avium Complex Isolated Using Bronchoscopy. Open Respir Med J 2016; 10:20-8. [PMID: 27335625 PMCID: PMC4892172 DOI: 10.2174/1874306401610010020] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/02/2015] [Revised: 02/13/2016] [Accepted: 02/15/2016] [Indexed: 11/22/2022] Open
Abstract
Introduction: The incidence of Mycobacterium avium complex (MAC)-positive respiratory specimen cultures and MAC lung disease (MACLD) is increasing worldwide. This retrospective study aimed to assess the association between MAC culture-positive bronchoscopy specimens and lung cancer. Materials and Methods: The medical records of 1382 untreated lung cancer patients between 2003 and 2011 were collected using our hospital database. Of them, records for 1258 that had undergone bronchoscopy together with sampling for mycobacterial culture were reviewed. Patient characteristics were compared between those with MAC-positive/other nontuberculous mycobacteria (NTM)-negative bronchial washings and those with MAC-negative/other NTM-negative bronchial washings. Patients with MAC-positive lung cancer were cross-sectionally divided into MACLD and non-MACLD groups, and their features were assessed. Follow-up data for patients with lung cancer but without MACLD were reviewed for subsequent development of MACLD. Results: Of the 1258 patients with lung cancer, 25 (2.0%) had MAC-positive/other NTM-negative bronchial washings. The proportion of women (52% vs 30%; P = 0.0274) and patient age (72 years vs 69 years; P = 0.0380) were significantly higher in the MAC-positive/other NTM-negative lung cancer group (n = 25) than in the MAC-negative/other NTM-negative lung cancer group (n = 1223). There were 10 patients with lung cancer and MACLD and 15 without MACLD; significant differences in patient characteristics were not found between the two groups, and none of the 15 patients without MACLD subsequently developed MACLD. Conclusion: MAC culture-positive bronchial washing is positively associated with lung cancer. Female sex and advanced age, but not lung cancer characteristics, were found to be associated with MAC infection in patients with lung cancer.
Collapse
Affiliation(s)
- Atsuhisa Tamura
- Center for Pulmonary Diseases and Respiratory Disease Division, National Hospital Organization Tokyo National Hospital, Kiyose, Tokyo 204-8585, Japan; Clinical Research Center and Pathology Division, National Hospital Organization Tokyo National Hospital, Kiyose, Tokyo 204-8585, Japan
| | - Akira Hebisawa
- Clinical Research Center and Pathology Division, National Hospital Organization Tokyo National Hospital, Kiyose, Tokyo 204-8585, Japan
| | - Kei Kusaka
- Center for Pulmonary Diseases and Respiratory Disease Division, National Hospital Organization Tokyo National Hospital, Kiyose, Tokyo 204-8585, Japan
| | - Takashi Hirose
- Center for Pulmonary Diseases and Respiratory Disease Division, National Hospital Organization Tokyo National Hospital, Kiyose, Tokyo 204-8585, Japan
| | - Junko Suzuki
- Center for Pulmonary Diseases and Respiratory Disease Division, National Hospital Organization Tokyo National Hospital, Kiyose, Tokyo 204-8585, Japan
| | - Akira Yamane
- Center for Pulmonary Diseases and Respiratory Disease Division, National Hospital Organization Tokyo National Hospital, Kiyose, Tokyo 204-8585, Japan
| | - Hideaki Nagai
- Center for Pulmonary Diseases and Respiratory Disease Division, National Hospital Organization Tokyo National Hospital, Kiyose, Tokyo 204-8585, Japan
| | - Takeshi Fukami
- Center for Pulmonary Diseases and Chest Surgery Division, National Hospital Organization Tokyo National Hospital, Kiyose, Tokyo 204-8585, Japan
| | - Ken Ohta
- Center for Pulmonary Diseases and Respiratory Disease Division, National Hospital Organization Tokyo National Hospital, Kiyose, Tokyo 204-8585, Japan
| | - Fumiaki Takahashi
- Clinical Research, Innovation and Education Center, Tohoku University Hospital, Sendai, Miyagi 980-8574, Japan
| |
Collapse
|
25
|
Takeda K, Ohshima N, Nagai H, Sato R, Ando T, Kusaka K, Kawashima M, Masuda K, Matsui H, Aono A, Chikamatsu K, Mitarai S, Ohta K. Six Cases of Pulmonary Mycobacterium shinjukuense Infection at a Single Hospital. Intern Med 2016; 55:787-91. [PMID: 27041166 DOI: 10.2169/internalmedicine.55.5460] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
Mycobacterium shinjukuense lung disease was diagnosed in 3 men and 3 women [mean age: 77.0±12.2 (57-93) years]. On imaging, 3 patients with previous pulmonary tuberculosis exhibited a fibrocavitary pattern, while the other 3 patients showed nodular bronchiectasis. A test with a tuberculosis rRNA identification kit (TRC Rapid(®) M. TB) was falsely positive for M. tuberculosis due to DNA sequence similarity in 16SrRNA. M. shinjukuense was identified by the gene sequences of rpoB, 16S rRNA, and hsp65. The symptoms and imaging findings of most of the patients have improved with chemotherapy with low minimum inhibitory concentrations of anti-tuberculosis drugs.
Collapse
Affiliation(s)
- Keita Takeda
- Center for Pulmonary Diseases, National Hospital Organization Tokyo National Hospital, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
26
|
Takahashi M, Kita Y, Kusaka K, Mizuno A, Goto-Yamamoto N. Evaluation of microbial diversity in the pilot-scale beer brewing process by culture-dependent and culture-independent method. J Appl Microbiol 2015; 119:904. [DOI: 10.1111/jam.12900] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- M. Takahashi
- National Research Institute of Brewing (NRIB); Higashi-Hiroshima Japan
| | - Y. Kita
- National Research Institute of Brewing (NRIB); Higashi-Hiroshima Japan
| | - K. Kusaka
- National Research Institute of Brewing (NRIB); Higashi-Hiroshima Japan
| | - A. Mizuno
- National Research Institute of Brewing (NRIB); Higashi-Hiroshima Japan
| | - N. Goto-Yamamoto
- National Research Institute of Brewing (NRIB); Higashi-Hiroshima Japan
| |
Collapse
|
27
|
Okubo M, Fujita A, Saito Y, Komaki H, Ishiyama A, Takeshita E, Kojima E, Koichihara R, Saito T, Nakagawa E, Sugai K, Yamazaki H, Kusaka K, Tanaka H, Miyake N, Matsumoto N, Sasaki M. A family of distal arthrogryposis type 5 due to a novelPIEZO2mutation. Am J Med Genet A 2015; 167A:1100-6. [DOI: 10.1002/ajmg.a.36881] [Citation(s) in RCA: 33] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/20/2014] [Accepted: 10/17/2014] [Indexed: 01/13/2023]
Affiliation(s)
- Mariko Okubo
- Department of Child Neurology; National Center of Neurology and Psychiatry; Japan
| | - Atsushi Fujita
- Department of Human Genetics; Yokohama City University Graduate School of Medicine; Japan
| | - Yoshiaki Saito
- Department of Child Neurology; National Center of Neurology and Psychiatry; Japan
| | - Hirofumi Komaki
- Department of Child Neurology; National Center of Neurology and Psychiatry; Japan
| | - Akihiko Ishiyama
- Department of Child Neurology; National Center of Neurology and Psychiatry; Japan
| | - Eri Takeshita
- Department of Child Neurology; National Center of Neurology and Psychiatry; Japan
| | - Emiko Kojima
- Department of Child Neurology; National Center of Neurology and Psychiatry; Japan
| | - Reiko Koichihara
- Department of Child Neurology; National Center of Neurology and Psychiatry; Japan
| | - Takashi Saito
- Department of Child Neurology; National Center of Neurology and Psychiatry; Japan
| | - Eiji Nakagawa
- Department of Child Neurology; National Center of Neurology and Psychiatry; Japan
| | - Kenji Sugai
- Department of Child Neurology; National Center of Neurology and Psychiatry; Japan
| | - Hiroko Yamazaki
- Department of Ophthalmology; National Center of Neurology and Psychiatry; Japan
| | - Kei Kusaka
- Center for Pulmonary Disease; National Hospital Organization Tokyo National Hospital; Japan
| | - Hiroshi Tanaka
- Department of Orthopedics; National Rehabilitation Center for Children with Disabilities; Japan
| | - Noriko Miyake
- Department of Human Genetics; Yokohama City University Graduate School of Medicine; Japan
| | - Naomichi Matsumoto
- Department of Human Genetics; Yokohama City University Graduate School of Medicine; Japan
| | - Masayuki Sasaki
- Department of Child Neurology; National Center of Neurology and Psychiatry; Japan
| |
Collapse
|
28
|
Takahashi M, Kita Y, Kusaka K, Mizuno A, Goto-Yamamoto N. Evaluation of microbial diversity in the pilot-scale beer brewing process by culture-dependent and culture-independent method. J Appl Microbiol 2015; 118:454-69. [DOI: 10.1111/jam.12712] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/09/2014] [Revised: 11/06/2014] [Accepted: 11/24/2014] [Indexed: 11/29/2022]
Affiliation(s)
- M. Takahashi
- National Research Institute of Brewing (NRIB); Higashi-Hiroshima Japan
| | - Y. Kita
- National Research Institute of Brewing (NRIB); Higashi-Hiroshima Japan
| | - K. Kusaka
- National Research Institute of Brewing (NRIB); Higashi-Hiroshima Japan
| | - A. Mizuno
- National Research Institute of Brewing (NRIB); Higashi-Hiroshima Japan
| | - N. Goto-Yamamoto
- National Research Institute of Brewing (NRIB); Higashi-Hiroshima Japan
| |
Collapse
|
29
|
Ogo S, Ichikawa K, Kishima T, Matsumoto T, Nakai H, Kusaka K, Ohhara T. A Functional [NiFe]Hydrogenase Mimic That Catalyzes Electron and Hydride Transfer from H2. Science 2013; 339:682-4. [DOI: 10.1126/science.1231345] [Citation(s) in RCA: 210] [Impact Index Per Article: 19.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022]
|
30
|
Tamura A, Higaki N, Kusaka K, Akashi S, Suzuki J, Shimada M, Suzuki J, Kawashima M, Suzuki J, Oshima N, Masuda K, Matsui H, Yamane A, Nagai H, Nagayama N, Toyota E, Akagawa S, Hebisawa A, Shoji S, Ohta K. Doctor's delay in endobronchial tuberculosis. Kekkaku 2013; 88:9-13. [PMID: 23513562] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/01/2023]
Abstract
OBJECTIVE The aim of this study was to investigate the current status of doctor's delay in diagnosing endobronchial tuberculosis (EBTB) and to elucidate the risk factors contributing to the delay. METHODS Retrospective clinicopathological analysis. PATIENTS Sixty-two patients with EBTB were admitted at our hospital between 1999 and 2010. Their backgrounds, symptoms, diagnoses at initial consultation, delay in diagnosis, and clinical examination results were analyzed. RESULTS Of the 62 patients, 59 had acid-fast, bacillipositive sputum smear test results at admission. Among the 40 patients with total diagnostic delay of more than 2 months, only 11 experienced long patient's delay exceeding 2 months. However, 22 patients experienced long doctor's delay of more than 2 months (28% vs. 55%, respectively, p < 0.05), suggesting that doctor's delay contributes more to total delay than patient's delay. Fever was less frequent in patients with long doctor's delays than in those without (0% vs. 18%, respectively), at the initial consultation. In addition, radiographs showed that patients with long doctor's delays more frequently presented with shadows in the lower lung field (50% vs. 23%, p < 0.05), and most of these patients had noncavitary shadows on admission. All 7 patients diagnosed with bronchial asthma at the initial consultation had long doctor's delays. CONCLUSION These findings demonstrate that long doctor's delays in diagnosing EBTB remain an issue. The clinical features of EBTB with long doctor's delays were confirmed to be quite different from those of pulmonary tuberculosis.
Collapse
Affiliation(s)
- Atsuhisa Tamura
- Department of Respiratory Diseases, National Hospital Organization Tokyo National Hospital, Tokyo, Japan.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
31
|
Hosoya T, Nakamura T, Katagiri M, Ebine M, Birumachi A, Kusaka K, Tomoyori K, Yamada T, Yokoyama T, Ohhara T, Kurihara K, Niimura N, Tanaka I, Soyama K. Developments for upgrades of two-dimension scintillator detector system, data acquisition electronics and software for J-PARC. Acta Crystallogr A 2011. [DOI: 10.1107/s0108767311083486] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022] Open
|
32
|
Kawasaki A, Takano K, Takahashi M, Ohhara T, Ohshima K, Kusaka K, Tanaka I, Yamada T, Hosoya T, Kurihara K, Niimura N. Crystal structure of C 4H 8ONH 2-PbBr 3by neutron and X-ray diffraction experiments. Acta Crystallogr A 2011. [DOI: 10.1107/s0108767311081578] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
33
|
Kusaka K, Yamada T, Hosoya T, Ohhara T, Kurihara K, Tomoyori K, Yokoyama T, Tanaka I, Niimura N. The first neutron structure analysis of protein with iBIX in J-PARC. Acta Crystallogr A 2011. [DOI: 10.1107/s0108767311081463] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
34
|
Niimura N, Chatake T, Tanaka I, Kusaka K. Proton polarization technique for neutron protein crystallography (NPC). Acta Crystallogr A 2011. [DOI: 10.1107/s0108767311081529] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022] Open
|
35
|
Yokoyama T, Nabeshima Y, Hosoya T, Ohhara T, Kurihara K, Kusaka K, Mizuguchi M, Tanaka I, Niimura N. Preliminary neutron crystallographic study of mutant transthyretin. Acta Crystallogr A 2011. [DOI: 10.1107/s0108767311092476] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
36
|
Tanaka I, Kusaka K, Hosoya T, Kazuo K, Ohhara T, Yamada T, Tomoyori K, Yokoyama T, Niimura N. Overview of the Ibaraki Biological Crystal Diffractometer (iBIX) at J-PARC. Acta Crystallogr A 2011. [DOI: 10.1107/s0108767311081517] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
37
|
Ishii T, Matsui Y, Nagayama N, Higaki N, Tone K, Kusaka K, Senoo M, Ariga H, Ohshima N, Masuda K, Matsui H, Teramoto S, Yamane A, Tamura A, Nagai H, Akagawa S, Toyota E, Shoji S, Nakajima Y. [A case of tuberculous pleurisy developing contralateral effusion during anti-tuberculosis chemotherapy]. Kekkaku 2011; 86:723-727. [PMID: 21922782] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/31/2023]
Abstract
A 55-year-old woman was admitted to our hospital because of chest pain, fever, and right pleural effusion that was exudative and lymphocyte-dominant with a high level of adenosine deaminase (ADA). Since her blood QuantiFERON-TB 3G test (QFT) was positive, she was diagnosed with tuberculous pleurisy. After initiation of anti-tuberculosis chemotherapy with isoniazid, rifampicin, ethambutol, and pyrazinamide, her symptoms improved. Later, liquid culture of the pleural effusion turned positive for Mycobacterium tuberculosis. On the 18th day of treatment, her chest X-ray and computed tomography exhibited pleural effusion in a moderate amount in the left thorax, with subsiding pleural effusion in the right thorax. Thoracocentesis demonstrated that the left thorax effusion was also exudative and lymphocyte-dominant, with elevated QFT response and high ADA concentration, suggesting tuberculous pleurisy. Mycobacterium tuberculosis was detected in the culture of a left pleural biopsy specimen obtained by thoracoscopy. We assumed that the left pleural effusion was due to paradoxical worsening because (1) on admission no effusion or lung parenchymal lesion was detected in the left hemithorax, (2) on the 14th day of treatment she was afebrile without pleural effusion on both sides, and (3) the bacilli were sensitive to the drugs she had been taking regularly. We performed drainage of the left effusion and continued the same anti-tuberculosis drugs, which led to the elimination of all her symptoms and of the pleural effusion on both sides. In conclusion, paradoxical worsening should be included in the differential diagnosis when contralateral pleural effusion is detected during the treatment of tuberculosis.
Collapse
Affiliation(s)
- Takashi Ishii
- Department of Respiratory Medicine, Center for Pulmonary Diseases, National Hospital Organization Tokyo National Hospital, Japan.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
38
|
Nakagawa T, Higurashi Y, Ohnishi J, Aihara T, Tamura M, Uchiyama A, Okuno H, Kusaka K, Kidera M, Ikezawa E, Fujimaki M, Sato Y, Watanabe Y, Komiyama M, Kase M, Goto A, Kamigaito O, Yano Y. First results from the new RIKEN superconducting electron cyclotron resonance ion source (invited). Rev Sci Instrum 2010; 81:02A320. [PMID: 20192341 DOI: 10.1063/1.3259232] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/28/2023]
Abstract
The next generation heavy ion accelerator facility, such as the RIKEN radio isotope (RI) beam factory, requires an intense beam of high charged heavy ions. In the past decade, performance of the electron cyclotron resonance (ECR) ion sources has been dramatically improved with increasing the magnetic field and rf frequency to enhance the density and confinement time of plasma. Furthermore, the effects of the key parameters (magnetic field configuration, gas pressure, etc.) on the ECR plasma have been revealed. Such basic studies give us how to optimize the ion source structure. Based on these studies and modern superconducting (SC) technology, we successfully constructed the new 28 GHz SC-ECRIS, which has a flexible magnetic field configuration to enlarge the ECR zone and to optimize the field gradient at ECR point. Using it, we investigated the effect of ECR zone size, magnetic field configuration, and biased disk on the beam intensity of the highly charged heavy ions with 18 GHz microwaves. In this article, we present the structure of the ion source and first experimental results with 18 GHz microwave in detail.
Collapse
Affiliation(s)
- T Nakagawa
- Nishina Center for Accelerator Based Science, RIKEN, Hirosawa 2-1, Wako, Saitama 351-0198, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
39
|
Nakamura T, Kobayashi N, Kondo Y, Satou Y, Aoi N, Baba H, Deguchi S, Fukuda N, Gibelin J, Inabe N, Ishihara M, Kameda D, Kawada Y, Kubo T, Kusaka K, Mengoni A, Motobayashi T, Ohnishi T, Ohtake M, Orr NA, Otsu H, Otsuka T, Saito A, Sakurai H, Shimoura S, Sumikama T, Takeda H, Takeshita E, Takechi M, Takeuchi S, Tanaka K, Tanaka KN, Tanaka N, Togano Y, Utsuno Y, Yoneda K, Yoshida A, Yoshida K. Halo structure of the island of inversion nucleus 31Ne. Phys Rev Lett 2009; 103:262501. [PMID: 20366309 DOI: 10.1103/physrevlett.103.262501] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/09/2009] [Indexed: 05/29/2023]
Abstract
The cross sections for single-neutron removal from the very neutron-rich nucleus 31Ne on Pb and C targets have been measured at 230 MeV/nucleon using the RIBF facility at RIKEN. The deduced large Coulomb breakup cross section of 540(70) mb is indicative of a soft E1 excitation. Comparison with direct-breakup model calculations suggests that the valence neutron of 31Ne occupies a low-l orbital (most probably 2p(3/2)) with a small separation energy (S(n) approximately < 0.8 MeV), instead of being predominantly in the 1f(7/2) orbital as expected from the conventional shell ordering. These findings suggest that 31Ne is the heaviest halo system known.
Collapse
Affiliation(s)
- T Nakamura
- Department of Physics, Tokyo Institute of Technology, 2-12-1 O-Okayama, Meguro, Tokyo 152-8551, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
40
|
Doornenbal P, Scheit H, Aoi N, Takeuchi S, Li K, Takeshita E, Wang H, Baba H, Deguchi S, Fukuda N, Geissel H, Gernhäuser R, Gibelin J, Hachiuma I, Hara Y, Hinke C, Inabe N, Itahashi K, Itoh S, Kameda D, Kanno S, Kawada Y, Kobayashi N, Kondo Y, Krücken R, Kubo T, Kuboki T, Kusaka K, Lantz M, Michimasa S, Motobayashi T, Nakamura T, Nakao T, Namihira K, Nishimura S, Ohnishi T, Ohtake M, Orr NA, Otsu H, Ozeki K, Satou Y, Shimoura S, Sumikama T, Takechi M, Takeda H, Tanaka KN, Tanaka K, Togano Y, Winkler M, Yanagisawa Y, Yoneda K, Yoshida A, Yoshida K, Sakurai H. Spectroscopy of 32Ne and the "Island of Inversion". Phys Rev Lett 2009; 103:032501. [PMID: 19659270 DOI: 10.1103/physrevlett.103.032501] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/15/2009] [Indexed: 05/28/2023]
Abstract
We report on the first spectroscopic study of the N=22 nucleus 32Ne at the newly completed RIKEN Radioactive Ion Beam Factory. A single gamma-ray line with an energy of 722(9) keV was observed in both inelastic scattering of a 226 MeV/u 32Ne beam on a carbon target and proton removal from 33Na at 245 MeV/u. This transition is assigned to the deexcitation of the first Jpi=2+ state in 32Ne to the 0+ ground state. Interpreted through comparison with state-of-the-art shell-model calculations, the low excitation energy demonstrates that the "island of inversion" extends to at least N=22 for the Ne isotopes.
Collapse
Affiliation(s)
- P Doornenbal
- RIKEN Nishina Center, Wako, Saitama 351-0198, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
41
|
Aoi N, Takeshita E, Suzuki H, Takeuchi S, Ota S, Baba H, Bishop S, Fukui T, Hashimoto Y, Ong HJ, Ideguchi E, Ieki K, Imai N, Ishihara M, Iwasaki H, Kanno S, Kondo Y, Kubo T, Kurita K, Kusaka K, Minemura T, Motobayashi T, Nakabayashi T, Nakamura T, Nakao T, Niikura M, Okumura T, Ohnishi TK, Sakurai H, Shimoura S, Sugo R, Suzuki D, Suzuki MK, Tamaki M, Tanaka K, Togano Y, Yamada K. Development of large deformation in 62Cr. Phys Rev Lett 2009; 102:012502. [PMID: 19257184 DOI: 10.1103/physrevlett.102.012502] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/03/2008] [Indexed: 05/27/2023]
Abstract
The structure of neutron-rich isotopes 60Cr and 62Cr was studied via proton inelastic scattering in inverse kinematics. The deformation lengths (delta) for 60Cr and 62Cr were extracted as 1.12(16) and 1.36(14) fm, respectively, providing evidence for enhanced collectivity in these nuclei. An excited state at 1180(10) keV in 62Cr was identified for the first time. We adopted 4;{+} as its spin and parity, leading to the rapid increase of the Ex(4;{+})/E_{x}(2;{+}) ratio, which indicates the development of large deformation in 62Cr near N=40. Importance of the admixture of the gd-shell component above N=40 is also discussed by comparing with a modern shell model calculation.
Collapse
Affiliation(s)
- N Aoi
- RIKEN Nishina Center, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
42
|
Tanaka I, Kusaka K, Tomoyori K, Niimura N, Ohhara T, Kurihara K, Hosoya T, Ozeki T. A new biological neutron diffractometer (iBIX) in J-PARC. Acta Crystallogr A 2008. [DOI: 10.1107/s0108767308094129] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
43
|
Kusaka K, Ohhara T, Kurihara K, Tanaka I, Hosoya T, Tomoyori K, Ozeki T, Niimura N. Optimization of design parameters of IBARAKI Biological Crystal Diffractometer (iBIX) in J-PARC. Acta Crystallogr A 2008. [DOI: 10.1107/s0108767308094117] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
44
|
Kurihara K, Ohhara T, Kusaka K, Niita K, Hosoya T, Tomoyori K, Niimura N, Tanaka I. Optics and shielding of IBARAKI Biological Crystal Diffractometer (iBIX) in J-PARC. Acta Crystallogr A 2008. [DOI: 10.1107/s0108767308094105] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022] Open
|
45
|
Ohhara T, Kusaka K, Hosoya T, Kurihara K, Tomoyori K, Niimura N, Tanaka I, Suzuki J, Nakatani T, Otomo T, Matsuoka S, Tomita K, Nishimaki Y, Ajima T, Ryufuku S. Development of data-processing software for a TOF single-crystal neutron diffractometer at J-PARC. Acta Crystallogr A 2008. [DOI: 10.1107/s0108767308094087] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
46
|
Yamada T, Kawamura K, Onishi Y, Ishikawa T, Kusaka K, Tanaka I, Niimura N. Crystallization of serine proteases for neutron single-crystal structure determination. Acta Crystallogr A 2008. [DOI: 10.1107/s0108767308092362] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
47
|
Takubo Y, Sato T, Asaoka N, Kusaka K, Akiyama T, Muroo K, Yamamoto M. Emission- and fluorescence-spectroscopic investigation of a glow discharge plasma: absolute number density of radiative and nonradiative atoms in the negative glow. Phys Rev E Stat Nonlin Soft Matter Phys 2008; 77:016405. [PMID: 18351942 DOI: 10.1103/physreve.77.016405] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/06/2007] [Revised: 10/03/2007] [Indexed: 05/26/2023]
Abstract
The excited-state atom densities in the negative glow of a direct-current glow discharge are derived from the spectral-line intensity of radiative atoms and the resonance-fluorescence photon flux of nonradiative atoms. The discharge is operated in a helium-argon gas mixture (molar fraction ratio 91:9; total gas pressure 5 Torr) at a dc current of 0.7-1.2 mA. The observations are made in the region of the maximum luminance in the cathode region, where high-energy electrons accelerated in the cathode fall are injected into the negative glow. The emission intensities of the He I, He II, Ar I, and Ar II spectral lines are measured with a calibrated tungsten ribbon lamp as an absolute spectral-radiance standard. Fluorescence photons scattered by helium and argon atoms in the metastable state and argon atoms in the resonance state are detected by the laser-induced fluorescence (LIF) method with the Rayleigh scattering of nitrogen molecules as an absolute standard of scattering cross section. The laser absorption method is incorporated to confirm the result of the LIF measurement. Excitation energies of the measured spectral lines range from 11.6 (Ar I) to 75.6 eV (He II), where the excitation energy is measured from the ground state of the neutral atom on the assumption that, in the plasma of this study, both the neutral and the ionic lines are excited by electron impact in a single-step process from the ground state of the corresponding neutral atoms. Experimental evidence is shown for the validity of this assumption.
Collapse
Affiliation(s)
- Y Takubo
- Department of Applied Physics, Tokyo University of Agriculture and Technology, Koganei, Tokyo 184-8588, Japan
| | | | | | | | | | | | | |
Collapse
|
48
|
Yu F, Takahashi T, Moriya J, Kawaura K, Yamakawa J, Kusaka K, Itoh T, Sumino H, Morimoto S, Kanda T. Angiotensin-II receptor antagonist alleviates non-alcoholic fatty liver in KKAy obese mice with type 2 diabetes. J Int Med Res 2007; 34:297-302. [PMID: 16866024 DOI: 10.1177/147323000603400309] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022] Open
Abstract
We examined the effects of the angiotensin-II receptor antagonist candesartan on non-alcoholic fatty liver (NAFL) and circulating adiponectin concentrations in KKAy obese mice with type 2 diabetes mellitus. The KKAy mice were randomly assigned to receive either candesartan at a once-daily dose of 10 mg/kg (n = 5) or placebo (n = 5). The differences in liver weight, histological evaluation of hepatic lipid infiltration, serum adiponectin concentration and hepatic adiponectin mRNA levels between the two groups were determined on day 7 after treatment was initiated. Candesartan-treated mice demonstrated significantly lower liver weights and reduced lipid droplets in hepatic cells compared with control mice. The circulating adiponectin levels and hepatic expression of adiponectin mRNA were significantly higher in candesartan-treated mice than control mice. These results suggest that candesartan might alleviate NAFL through elevation of circulating adiponectin levels in KKAy obese mice with type 2 diabetes mellitus.
Collapse
Affiliation(s)
- F Yu
- Department of General Medicine, Kanazawa Medical University, Ishikawa, Japan
| | | | | | | | | | | | | | | | | | | |
Collapse
|
49
|
Kusaka K, Itoh T, Kawaura K, Moriya J, Yamakawa J, Takahashi T, Oguchi M, Tonami H, Yamamoto I, Kanda T. Advanced oesophageal carcinoma in an 84-year-old treated with chemoradiotherapy. J Int Med Res 2006; 34:437-40. [PMID: 16989502 DOI: 10.1177/147323000603400415] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Abstract
We present a case of advanced oesophageal cancer with cardiac invasion in an 84-year-old male presenting with dysphagia and general malaise. Histological analysis of an endoscopic biopsy specimen revealed a poorly differentiated squamous cell carcinoma. Computed tomography indicated a thickened oesophageal wall that was compressing the left atrium, suggesting invasion of the heart, and oesophagography revealed a polypoid lesion 9 cm in length. No distant metastases were seen on computed tomography. The patient was given chemotherapy with 10 mg/m2 cisplatin on days 1 and 4 every week for 5 weeks and concurrent radiotherapy at a dose of 2 Gy five times per week (total dose 52 Gy). After 4 weeks, the mass was no longer visible on oesophagography or endoscopic examination. The patient was free of recurrence and metastases for 4.5 years. In conclusion, chemoradiotherapy may be curative in elderly patients with unresectable oesophageal carcinoma.
Collapse
Affiliation(s)
- K Kusaka
- Department of General Medicine, Kanazawa Medical University, Ishikawa, Japan
| | | | | | | | | | | | | | | | | | | |
Collapse
|
50
|
Kusaka K, Itoh T, Kawaura K, Yamakawa J, Takahashi T, Kanda T. Three-point fixation of stomach to abdominal wall in the percutaneous endoscopic gastrostomy procedure. Endoscopy 2005; 37:494. [PMID: 15844032 DOI: 10.1055/s-2005-861233] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/10/2022]
Affiliation(s)
- K Kusaka
- Department of General Medicine, Kanazawa Medical University, Ishikawa, Japan
| | | | | | | | | | | |
Collapse
|